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Abstract: Aberrant WNT signaling underlies cancerous transformation and growth in many
tissues, such as the colon, breast, liver, and others. Downregulation of the WNT pathway is a
desired mode of development of targeted therapies against these cancers. Despite the urgent
need, no WNT signaling-directed drugs currently exist, and only very few candidates have
reached early phase clinical trials. Among different strategies to develop WNT-targeting anti-cancer
therapies, repositioning of existing drugs previously approved for other diseases is a promising
approach. Nonsteroidal anti-inflammatory drugs like aspirin, the anti-leprotic clofazimine, and the
anti-trypanosomal suramin are among examples of drugs having recently revealed WNT-targeting
activities. In total, 16 human-use drug compounds have been found to be working through the WNT
pathway and show promise for their prospective repositioning against various cancers. Advances,
hurdles, and prospects of developing these molecules as potential drugs against WNT-dependent
cancers, as well as approaches for discovering new ones for repositioning, are the foci of the
current review.
Keywords: approved drugs; WNT pathway; repositioning
1. Introduction
WNT signaling is one of the essential pathways involved in animal embryonic development,
during which it has numerous roles including the regulation of cell proliferation and differentiation [1].
In the healthy adult tissues however, it is largely inactive, with some exceptions such as the renewal of
the gastro-intestinal tract [2], as well as haematopoiesis [3] and regeneration after injury [4]. It is to no
surprise then that aberrant activation of this pathway can lead to diseases of neoplastic nature such as
cancer [1,5].
The signaling is activated by a family of lipoglycoproteins called WNTs, of which 19 can be found
in humans and whose production, secretion and diffusion through tissues is tightly controlled [6].
Upon binding to the FZD family of GPCRs [7,8] (ten homologues in humans), various branches
of the WNT pathway can be activated, depending on the ligand-receptor combination and cellular
context. They are namely the PCP branch mostly involved in cytoskeleton rearrangement, cell polarity
and migration; the WNT/Ca2+ branch which is known to promote proliferation and antagonize the
canonical pathway; and finally the so-called canonical branch [9]. It is the latter, which is mostly
associated with disease and cancer and therefore is the focus of many studies touching upon the WNT
pathway [1,10]. Upon WNT binding to the FZD-receptor and one of the two single transmembrane
co-receptors LRP5/6, the FZD-coupled G-proteins together with Dishevelled (DVL), a multi-domain
scaffolding protein, transduce the signal (Figure 1) [11,12]. As a consequence AXIN, part of the
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β-catenin destruction complex, is recruited to the membrane [13,14]. The destruction complex is
responsible for the phosphorylation of β-catenin and its subsequent degradation. In addition to AXIN,
which acts as a scaffold, it also contains adenomatous polyposis coli (APC) and the Ser/Thr kinases
casein kinase (CK1) and GSK3β, which in the absence of signaling phosphorylate β-catenin. The
phosphorylation of β-catenin results in its ubiquitination and proteosomal degradation [15]. However,
upon WNT signaling AXIN is no longer able to form the destruction complex and cytosolic β-catenin
accumulates. This leads to its translocation to the nucleus where it exerts its downstream effects by
mediating LEF/TCF dependent transcription of WNT-target genes. These include proto-oncogenes
such as c-Myc and cyclin D1 [16,17].
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descriptions of the activities refer to Table 1 and the corresponding sections in the main text.
To date nearly half of known human tumors show a dysregulation of the WNT signaling
pathway [18]. Loss-of-function mutations of APC, which induce adenoma, one of the first steps in the
cancerous development, are of the first and probably the best known examples of WNT-dependency in
cancer [19]. Since establishi g the link between the WNT pathway and tumor genesis, a bro d variety
of solid tumors and leuka mias h ve bee shown to eit r almost entirely or by few subtypes depend
on deregulation of the WNT-pathway [18]. Even though the overactivation of the pathway is in some
cases due to mutations, in many it is rather the up- or downregulation of pathway components which
is the cause. Examples therefor are the upregulation of the WNT receptor FZD7 found in certain breast
cancers and hepatocellular carcinoma [20,21] or the downregulation of the WNT inhibitory factor 1
(WIF1) found in prostate, lung, breast and bladder cancers [22]. More recently, the WNT-pathway
has also been shown to be a player in an emerging field of cancer stem cells (CSC), being involved in
their maintenance and survival in certain cancers [23,24], resparking the interest of researchers from
various fields in this pathway. In several instances CSCs, thought to be tumor initiating cells, have been
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demonstrated to be a cause for the occurring drug resistance and metastasis after initial therapy [25].
It is therefore not surprising that in recent years there has been an urgency to discover new drugs
targeting this pathway. So far however, no drug targeting the WNT pathway has been approved,
and only few have made it into early clinical trials, such as the anti-FZD7 antibody vantictumab
(NCT01345201) and the PORCN inhibitor LGK974 (NCT01351103) [26].
The traditional drug discovery process has become a costly and time-consuming practice [27,28].
On average, de novo discovery and development of a drug costs about 1.8 billion dollars and it takes
around 10–15 years for the drug to reach the market [27]. On estimate, only one in ten drugs entering
phase I clinical trials is finally approved by the FDA, and this decreases to one in fifteen for drugs with
an oncology indication [28]. Drug repositioning, meaning using known drugs for new purposes, has
therefore become an attractive drug development strategy, as it has an attractive risk-versus-reward
trade-off compared to other business strategies [29]. Indeed, the advantages of repositioning a drug
are multiple: not only has the drug already been used in humans, been tested in various stages of the
drug development pipeline and therefore offers knowledge on is safety, pharmacology and toxicology,
but also in some cases, later stages of the process such as the manufacturing and formulation can
be reused for the new drug product [29]. Especially in oncology, where there is an ever-increasing
demand for new therapies, drug repositioning could offer a faster and economically more interesting
way of fighting this class of disease [30]. The best-known example of successful drug repositioning
against cancer is thalidomide. It was initially used to treat morning sickness but was discontinued after
being discovered to cause malformations in new-borns. It was later rediscovered to have anti-cancer
properties and is currently FDA-approved for multiple myeloma in combination treatment with
dexamethasone [30].
Many WNT-dependent cancers, such as triple-negative breast cancer (TNBC), are unmet medical
needs. This makes future drugs against these cancers eligible for receiving the fast track designation
granted by the FDA. This designation allows the approval process to be accelerated [31]. We
propose that the shortened drug discovery process together with fast track designation makes drug
repositioning a promising strategy to win the battle against WNT-dependent cancers, bringing help to
patients sooner than later.
This review focuses on approved drugs, which have later been found to modulate the WNT
pathway. We highlight their mechanism of action and the range of WNT-dependent cancers these
drugs may target in vitro and in vivo. We also correlate these data with the pharmacodynamic
and pharmacokinetic parameters established for these drugs, and examine the potential for
their repositioning against the WNT-dependent cancers. Finally, we discuss the challenges drug
repositioning holds and future possibilities of finding new anti-WNT drugs for cancer treatment.
2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
NSAIDs are a class of drugs marketed for their analgesic, anti-inflammatory and anti-pyretic
effects. These effects are achieved by the inhibition of the cyclooxygenase (COX) enzymes, COX1 and
COX2, involved in the prostaglandin production. They can be classified as non-selective, as is the case
for most of the NSAIDs, or selective COX2 inhibitors, as is the case for celecoxib [32].
Apart from their traditional usage, aspirin and other NSAIDs have shown great promise in
lowering the incidence of adenomatous polyposis of the colon and reducing the risk of colon cancer.
This conclusion is based on several epidemiological studies of the general population and randomized
trials [33–36]. Studied to a lesser extent, the prolonged intake of NSAID has also been linked to a
reduction of incidence of various other solid tumors [37,38] such as those of the breast [39,40], lung [41],
oesophagus [42], prostate [43], bladder [44], and pancreas [45].
The existence of crosstalk between COX2 and WNT signaling has been demonstrated. Indeed,
prostaglandin E2 (PGE2) induces β-catenin stabilization, leading to its nuclear translocation, and
is able to induce β-catenin/TCF/LEF-reporter activity in colon cancer cells [46,47]. Castellone et al.
showed that stimulation of the GPCR EP2 by its ligand PGE2 induces activation of Gαs and its
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association with AXIN, leading to the release of GSK3β from the destruction complex. In parallel, the
Gβγ component of the initial heterotrimeric Gs protein activates PI3K/AKT, which in turn inhibits
GSK3β by phosphorylation. PGE2 therefore has a dual activating effect on the WNT-pathway, and
NSAIDs decrease this effect by inhibiting the COX enzymes [46]. The effectiveness of NSAIDs on
cancer is in some cases partly due to the COX-inhibitory effect, which leads to lower levels of PGE2
production and decreases the β-catenin stabilization [48,49]. In the sections below, we summarize
the experimental evidence demonstrating that NSAIDs also target the WNT/β-catenin pathway in
COX2-independent manners.
2.1. Sulindac
Multiple studies have shown that sulindac is able to increase β-catenin degradation and decrease
its nuclear translocation in breast, lung and colon cancer cells in vitro, leading to reduced expression
of the β-catenin/TCF target genes [50–52]. This was also observed in X-RARalpha-expressing cells,
reducing their leukemic phenotype and stemness [53]. A metabolite, sulindac sulfide, has demonstrated
WNT/β-catenin signaling blockage and inhibition of proliferation of prostate cancer cells [54].
From a mechanistic point of view, sulindac has been shown to directly affect the WNT-pathway
independently of the COX expression. Sulindac is also one of the few WNT-active approved drugs
for which the exact molecular targets within the pathway have been described. Sulindac is able to
specifically bind to the DVL-PDZ domain, which was proposed to directly inhibit DVL’s interaction
with FZDs. Surprisingly, this interaction is characterized by low micromolar Kd levels [55], while the
IC50 of the pathway inhibition by sulindac was found to be almost two orders of magnitude higher [50,52].
This discrepancy might be accounted for by the fact that the most prevalent cell-permeable metabolite
of this drug (sulindac sulfide) has a reduced affinity to DVL [55]. Additionally, it has been
demonstrated that sulindac is a cyclic guanosine 31,51-monophosphate phosphodiesterase (cGMP PDE)
inhibitor, which leads to elevated levels of cGMP and activated cGMP-dependent protein kinase (PKG).
This in turn results in transcriptional suppression of β-catenin and inhibition of the WNT/β-catenin
pathway [56]—potentially more powerfully than the inhibition of DVL-FZD interactions.
Further, sulindac has been shown to effectively reduce tumor growth of colon cancer and intestinal
cancer cells in vivo and prevent colon cancer metastasis in mouse models [48,57,58]. The daily
doses of sulindac tested in vivo were 20–50 mg/kg, however doses above 20 mg/kg have shown
significant toxicity. It should be noted that in order to achieve efficient in vivo inhibition of COX2 by
sulindac 10- to 20-fold lower doses are used, indicating a very narrow therapeutic window available to
achieve maximal anti-WNT effect. Even at borderline to over toxicity dose of sulindac at 20 mg/kg,
plasma levels of the drug were just under 20–40 µM [59], which is somewhat lower than the IC50 of
COX-independent WNT-inhibition in vitro (50–70 µM) [50,52]. However, this might be compensated
by the tissue accumulation of sulindac, exceeding plasma levels by 3–5 fold [59]. Sulindac treatment
in mice results in reduced transcript and nuclear β-catenin levels [58,60,61]. In humans, familial
adenomatous polyposis (FAP) patients treated with a tolerable dose of 300 mg of sulindac per day for 6
months presented lower adenoma nuclear β-catenin levels than adenomas in non-treated patients [50].
However, at this dose sulindac plasma and tissue levels will not exceed 1–10 µM and therefore
WNT-pathway modulation in these patients is likely to be a result of COX2 inhibition.
2.2. Aspirin
The chemopreventive effects of aspirin, the only irreversible COX inhibitor, were first reported in
a study in 1988 [62] and since, there have been many clinical reports to support such effects [34,36,63].
Diehlmann et al. were the first to demonstrate that aspirin can inhibit β-catenin/TCF transcriptional
activity in a luciferase-based reporter assay in colorectal cells lacking COX expression [64]. The
drug did not affect the total amount of β-catenin, but the levels of β-catenin phosphorylation (both
phospho-S33/S37/T41-catenin and phospho-T41/S45-catenin) were increased, however independently
of GSK3β [65]. It was thus hypothesized that aspirin affected β-catenin phosphorylation through
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inhibition of a phosphatase, which was later discovered to be protein phosphatase A2 (PP2A), being
inhibited by aspirin directly [66,67]. Although not yet clearly demonstrated, it is highly likely that
aspirin also affects WNT signaling indirectly through other aspirin affected pathways, for example the
NF-κB signaling [68]. In vivo models confirm the influence of aspirin on the WNT pathway. In APCmin
mice, the murine model of FAP, aspirin treatment decreased tumor formation and lowered β-catenin
levels [69]. Noteworthily, the amount of data accumulated on aspirin and its effect on various tumors
is tremendous and cannot be reviewed here fully. There are multiple studies confirming its effects on
WNT signaling and tumor growth in various cancer types both in vivo and in vitro. These findings are
excellently reviewed elsewhere [70,71].
In general, lower millimolar levels (~5 mM) of aspirin are needed for the COX-independent
in vitro inhibition of the WNT/β-catenin pathway in human cancer cells [64]. To reach similar
concentrations in mouse tumor tissue, high doses (ca. 100 mg/kg) of aspirin must be administered [72].
The chemopreventive effect of aspirin in humans, which has already been shown for doses as low as
75 mg/day [73] is most likely due to the COX inhibitory effects. In order to reach the COX-independent
WNT inhibitory effects of aspirin, high doses (>10 g/day) need to be administered [74], which however
could lead to toxicity and side effects upon treatment, especially in the long-term [75]. Aspirin’s merit
as a combination therapy is currently being scrutinized in various trials and retrospective studies,
which have already demonstrated its utility in treatment and prevention of notorious WNT-dependent
cancers such as breast, colon, prostate and gastric cancers [71]. The first tangible outcome in aspirin
repositioning has already been achieved. The US Preventive Services Task Force (USPSTF) recommends
a daily low-dose use for individuals with high risk of cardiovascular diseases (CVD) between 50 and
69 years as a mean of both CVD and colorectal cancer chemoprevention.
2.3. Indomethacin
Like aspirin, indomethacin has been shown to inhibit proliferation of colorectal cancer cells
independently of COX2 expression; however, the mechanisms of action of the two NSAIDS on
the WNT pathway were suggested to be different [76]. Indomethacin concentrations of 100–400 µM
significantly decrease the TopFlash transcriptional readout in these cells [64], and higher concentrations
intensify this inhibition and are accompanied by a decrease in the total β-catenin protein levels [76,77].
The exact reason or details for these effects remain unclear; however, they might partly result from
unusual transcriptional regulation of β-catenin, as mRNA levels of β-catenin were significantly lower
in the cells treated with indomethacin. The drug has also shown a differential effect on WNT target
genes: while cyclin D1 was expectedly downregulated, c-Myc was upregulated. The latter might be the
result of a swift onset of apoptosis due to indomethacin treatment [76]. Another input of indomethacin
in WNT inhibition is achieved through disruption of the β-catenin-TCF4 complex formation with
DNA in colorectal cancer in vitro models [78].
In the rat model of colon cancer, indomethacin (2 mg/kg) was able to reduce tumor formation [79],
eliminating nuclear β-catenin staining while leaving cytoplasmic levels unchanged in these tumors [61].
However, it is likely that the anti-WNT effects seen in these studies are mediated through COX
inhibition, since these doses result in plasma levels of ca. 10–30 µM of indomethacin [80], far below of
what is required for the strong and direct inhibition of the pathway. Applications of higher doses of
unmodified indomethacin are unlikely since they are expected to produce acute toxicity (LD50 of the
drug is around 14 mg/kg for rats).
2.4. Celecoxib
The COX2-independent effect of celecoxib was demonstrated by the induction of apoptosis in
celecoxib-treated HTC-116 cells, a colorectal cell line lacking the expression of COX2. The effect was
proposed to be mediated by inhibition of the WNT pathway, since the drug inhibited the TopFlash
reporter and cyclin D1 expression [81]. A second study further showed that in colon cancer cells,
celecoxib acted downstream of the β-catenin destruction complex, decreasing TCF1 and TCF4 levels
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by proteasomal degradation [82]. Complementary to these results, a study demonstrated that in
colon cancer cells celecoxib inhibited the c-Met/AKT pathway, resulting in decreased phosphorylation
and thus increased activity of GSK3β, leading to an increase in β-catenin phosphorylation [83]. The
inhibition of proliferation and the downregulation of the WNT/β-catenin signaling by celecoxib was
also demonstrated in glioblastoma and prostate cancer cells [54,84]. In glioblastoma cells, GSK3β
phosphorylation was shown to be reduced, leading to β-catenin phosphorylation similarly to the
effects observed in the colon cancer cells [84]. Analogous observations were made for hepatoma
cells [85] and osteosarcoma cells [86].
Celecoxib also affects CSCs. In colorectal CSCs, celecoxib reduces the chemotherapy-resistant
CD133-positive pool, while decreasing WNT activity and expression of stemness markers [87]. In
myelogenous leukaemia cells resistant to imatinib, celecoxib sensitized the cells by inhibiting the
ABC transporters responsible for drug resistance via WNT and RAS signaling pathways. The
study demonstrated downregulation of the WNT activity and pathway components such as GSK3β,
β-catenin, LEF1 and TCF4 at protein and mRNA levels [88].
In vivo celecoxib has been shown to prevent the formation of β-catenin accumulated crypts,
typical premalignant lesions of colon cancer showing excessive accumulation of β-catenin [89].
Further, celecoxib has been shown to suppress lung cancer cell metastasis in mice through the
PGE2-GSK3β-β-catenin axis [90]. Like sulindac and indomethacin, celecoxib is able to reduce the
amount of β-catenin-positive cells in colon cancer in rats [61]. Finally, celecoxib has been shown to
suppress WNT-dependent mammary carcinoma, meningioma and Lewis lung carcinoma in mouse
models [91,92]. The doses used in these studies correspond to plasma levels of 3–5 µM, which is
somewhat below the average 20 µM required for inhibition of tumor growth. However, the drug
can accumulate in tissues to concentrations 2–4 folds higher than in plasma and therefore reach the
effective dose [93]. FAP patients treated with celecoxib (400 mg/day) showed a 28% reduction in
polyps after 6 months [94], and in 1999 the FDA approved this drug for the indication of FAP but later
withdrew the approval due to lack of proof of clinical benefit.
3. Antiparasitics
3.1. Niclosamide
Niclosamide is an anthelmintic drug approved by the FDA in 1982 for treating intestinal parasite
infections, especially cestodes [95]. In addition to its anthelmintic activity, several studies have
described anticancer properties of niclosamide. Its anti-proliferative activity has been demonstrated
in a wide array of cancer cell lines representative of WNT-dependent cancers: non-small lung
carcinoma [96], multiple myeloma [97], hepatoma [98], adrenocortical carcinoma [99], ovarian
cancer [100] and glioblastoma [101]. It also suppresses the growth of CD34+/CD38´ CSCs of acute
myeloid leukemia (AML) and CD44+/CD24´ CSCs of basal-like breast cancer [102,103].
Niclosamide inhibits the canonical WNT pathway with an IC50 of 0.2–0.4 µM, similar to that
which mediates inhibition of cancer cells growth (0.33–0.75 µM) [104], suggesting that WNT inhibition
is involved in niclosamide’s anticancer effects. Several WNT components are involved in the inhibitory
action of niclosamide, which vary depending on the cancer subtypes. In osteosarcoma and colorectal
cell lines, it inhibits WNT3a-stimulated β-catenin stabilization and LEF/TCF reporter activity through
promotion of FZD1 endocytosis and downregulation of DVL2 [105,106]. However, niclosamide’s
inhibitory effect for breast and prostate cancer cells seems to involve other components of the WNT
pathway. Instead of DVL2 downregulation it induces LRP6 degradation associated with inhibition of
cell proliferation, invasion and migration of cancer cells [104].
In addition to inhibiting the canonical WNT pathway, niclosamide may mediate its anticancer
activities through several other signaling pathways such as NOTCH [107], MTOR [108], NF-κB [97]
and STAT3 [96]. This pleiotropy highlights the need of identifying the relevant targets of niclosamide
in different tumors.
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The anti-cancer effects of niclosamide have also been tested in vivo. When delivered orally at
200 mg/kg, it induces inhibition of tumor growth and impairs metastases formation in colorectal
cancer [106]. WNT pathway inhibition by niclosamide in colorectal and basal-like breast cancer models
in mice has been demonstrated by immunohistochemical analysis, where lower levels of cytosolic and
nuclear β-catenin were observed for the drug-treated mice [103,106]. When delivered directly into
the systemic circulation through intra-peritoneal (IP) injection, it resulted in a significant inhibition
of breast tumor growth [109], without manifesting any signs of toxicity or mutagenicity [99,101,103].
However, no information is available on its pharmacokinetics after IP or IV injections. In contrast, the
poor oral bioavailability of the drug limits its maximal plasma concentrations achievable by that route
of administration to 0.1–0.2 µM [106], one order of magnitude below the effective range; other studies
have also shown that the plasma concentrations can vary widely due to variable absorption rates
by the gastrointestinal tract [110]. These effects limit the anticancer applications of orally delivered
niclosamide. Since the safety profile is only available for oral delivery [110], it is only feasible to use
it against gastrointestinal tumors so far. One such study has already been launched: the evaluation
of efficacy as a treatment of metastatic colorectal cancers patients in a phase 2 clinical trial, using the
same approved dose and oral route of administration (NCT02519582) is ongoing.
3.2. Suramin
First introduced in 1912, suramin was used for the treatment of African sleeping sickness and
river blindness in humans [111]. Despite such a long history and appearance of new agents for the
same conditions, suramin is still indispensable in the clinical practice as it remains the only treatment
for certain subtypes of the diseases [112].
Suramin has demonstrated a dose-dependent anti-proliferative effect in many human cancer
cell lines [113–115]. Molecular targets of suramin are numerous. Most relevant for its anticancer
effects are the inhibition of binding of many growth factors, e.g., FGF and VEGF, to their cognate
receptors [116–118], and the folate metabolism [119]. Recently, we have added to this list inhibition
by suramin of at least two targets within the WNT pathway, resulting in its complete blockade [120].
While identification of the downstream target is currently ongoing, we investigated the upstream
target, since inhibition of the upstream components of the pathway is a promising approach for
increasing drug efficiency against WNT-dependent cancers [26,121,122]. We discovered that suramin
acted as a competitive inhibitor of GTP uptake by the heterometric G proteins, in turn regulating
internalization of the WNT/FZD complexes, which normally serves to amplify the signaling in the
WNT pathway [120,123,124]. We have further shown that inhibition of TNBC growth in vitro and
in vivo is more efficient at the concentrations ensuring such inhibition (ca. 200 µM) as compared to
lower doses.
Since suramin was already proposed as an anti-neoplastic agent in the late-80s, this drug has an
extensive record of clinical trials. Although trials with the focus on the WNT pathway targeting
are yet to be done, some have already been performed against cancers which strongly rely on
the WNT pathway, such as recurrent breast cancer [125,126], metastatic colorectal cancer [127,128],
and lung cancer [129]. Surprisingly, in almost all of these trials suramin failed to show any
significant improvements, maximally resulting in only moderate positive response reported in two
studies [125,129]. In both, suramin was used at small doses (weekly IV perfusions, ca. 100–150 mg
per patient) resulting in plasma levels of 30–50 µM; in these cases treatment was not associated with
any significant toxicity. In other studies, the doses (weekly IV, 500–700 mg per patient) used produced
plasma levels corresponding to that necessary for WNT inhibition (200–250 µM); unfortunately this
resulted in significant side effects, primarily of the neurological character with no significant clinical
outcomes for tumors [126–128]. One of the possible explanations for this might be in the unfavourable
pharmacokinetics of suramin. It was found to have poor tissue penetration and retention. Suramin
concentrations in most tissues were 2–3 times, and in the tumor (pheochromocytoma in this case)
almost six times lower than in plasma [130]. It should be also noted that suramin demonstrated
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similar negative results against other types of cancers: prostate [131–134], ovarian [130], urinary
bladder cancer [135]. Based on this negative data, the FDA has so far refused approval of suramin for
therapeutic applications in oncology [134].
Tackling these limitations of suramin can be achieved by several ways. Since systemic
administration of suramin results in multiple toxicities and the gastrointestinal tract has shown
poor absorption [111], the repositioning of suramin might be achieved by using new routes of
administration to avoid systemic treatment. This has led to a phase 1 clinical trial, testing the efficacy
of suramin delivered intravesically for urinary bladder cancer patients [135]. Future directions of
suramin applications might be through usage of novel targeted delivery systems to create high local
concentrations at the tumor site [136] or synthesis of new structural analogues in order to improve
potency and overcome the side effects [137–139].
3.3. Pyrvinium Pamoate
Pyrvinium pamoate is an anthelminthic drug approved by the FDA [140]. The anticancer activity
of pyrivinium is exhibited through inhibition of colon cancer cell motility and proliferation in vitro
and suppression of tumor growth in vivo [141].
Inhibition of the WNT pathway by pyrvinium has also been demonstrated in vitro [142,143]
and in vivo [141]. Like for most of the repositioned drugs, WNT inhibition by pyrvinium occurs
through multiple components of the pathway. Pyrivinium has been demonstrated to act through
activation of an isoform of casein kinase 1α (CK1α), part of the WNT pathway destruction complex.
In the same work, the authors identified inhibition of pygopus (PYGO), preventing transcriptional
activity of β-catenin, as a second impact of pyrvinium on the WNT pathway. These activities are
independent of each other and show comparable IC50’s [143]. However, another study has failed to
recapitulate the effects on CK1α by pyrivinium, and instead suggested that the drug acts through the
PI3K/AKT pathway in the manner similar to that described above for celecoxib, decreasing GSK3β
phosphorylation at Ser9 and thus enhancing its activity [142]. Several other mechanisms, such as the
energy metabolism and STAT3 pathway [144,145], glucose deprivation and hypoxia [146], as well as
autophagy [147], have been implicated in the anticancer action of pyrvinium.
In vitro studies have identified pyrvinium to be effective against the WNT pathway and cancer
cell proliferation within the high-nanomolar range (50–200 nM). When delivered by its standard oral
route, pyrvinium’s bioavailability is virtually zero [148] and therefore cannot be employed for in vivo
anticancer studies. Therefore, it was delivered by daily intraperitoneal injections of 1 mg/kg, which
were reported to create acceptable peak plasma levels of 150 nM [149]. Using this dose, efficient
suppression of the WNT-dependent colon cancer in vivo was achieved [141]. Unfortunately, this dose
is borderline with severe toxicity, since any increase resulted in severe toxic effects [149]. Therefore,
phase I safety trials should be launched first in order to verify this novel delivery route in patients; no
data has been reported so far for any attempts to run such a trial.
3.4. Ivermectin
First introduced in 1981 as an anti-parasitic for veterinary applications [150], ivermectin was
approved in 1987 for the treatment of onchocerciasis and more recently for lymphatic filariasis in
humans [151,152]. It has also been reported to activate chloride channels of nematodes, causing
parasite paralysis and death [153].
Ivermectin inhibits proliferation of human colon cancer and lung cancer cells both in vitro
and in vivo [154]. The anti-proliferative action, affecting both the bulk tumor cells and CSCs, was
linked in this study to inhibition of WNT signaling. The mechanism of this inhibition is rather
unusual: ivermectin inhibits C-terminal phosphorylation of β-catenin, overactivating by an unknown
mechanism protein phosphatases PP2A and PP1. As a result, the activity of β-catenin as a co-factor in
transcription of the WNT target genes is reduced [154].
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Ivermectin also has a cytotoxic action due to activation of mammalian chloride channels, similarly
to its effects in nematodes [155]. Importantly, the anti-WNT IC50 of ivermectin is 5–10 times
(~1–2 µM vs. 10 µM) lower than that of its toxic effect against chloride channels. Unfortunately,
oral bioavailability of the drug, as for other antiparasitic drugs discussed in this section, is very
low. Upon normal oral dosing its plasma levels do not exceed 60 nM. Intraperitoneal delivery at
10 mg/kg in the form of a cyclodextrin conjugate, likely achieving high plasma concentrations, was
well tolerated and suppressed growth of colorectal cancer in mouse xenograft studies [154]. Toxicity
studies in vivo have also demonstrated a wide therapeutic index for ivermectin [151,156]. The scarcity
of data regarding the pharmacokinetics and the safety profile of ivermectin delivered to humans by
means other than oral delivery make it compulsory for ivermectin to be tested in safety studies before
any further clinical interventions.
4. Antimicrobials
4.1. Salinomycin
The anticancer properties of salinomycin, an antibiotic potassium ionophore used to treat poultry,
were first discovered in a high-throughput screen on breast cancer stem cells [157]. This study
demonstrated the ability of salinomycin to reduce the proportion of breast CSCs in vitro and the
expression of genes associated with CSC and poor prognosis. Gupta et al. also showed inhibition of
mammary tumor growth in mice treated with salinomycin and the promotion of cell differentiation to
an epithelial phenotype after treatment [157]. Since then, salinomycin has been shown to inhibit cell
growth in the following WNT-dependent cancer cells in vitro: pancreatic [158], endometrial CSCs [159],
chronic lymphocytic leukaemia cells [160], breast and prostate cancer cells [161], osteosarcoma
CSCs [162], hepatocellular carcinoma cells [163], nasopharyngeal carcinoma cells [164]. It has also
showed promising inhibition of growth of gastric tumors, osteosarcoma as well as hepatocellular and
nasopharyngeal carcinoma in mice [162–165].
As the WNT pathway is one of the essential pathways responsible for the survival of CSCs,
it has been proposed as one of the targets of salinomycin [160]. Indeed the drug has been shown
to downregulate the expression of WNT-target genes such as LEF1, cyclin D1 and fibronectin
in vitro [159–161] by inhibiting the WNT-induced phosphorylation of the co-receptor LRP6 and
inducing its degradation in WNT-overexpressing cells [160,161]. Further it has been shown that
salinomycin is able to activate the transcription factor FOXO3, which then disturbs interactions
between β-catenin and TCF, inhibiting the transcription of WNT target genes [166]. One additional
suggested mechanism of action of salinomycin is the suppression of the canonical WNT-pathway via
an increase of intracellular calcium levels, as it has been shown that non-canonical WNT ligands are
able to inhibit canonical WNT-signaling by increasing calcium influx [163]. It should be noted that
non-WNT related mechanisms of action of salinomycin on cancer cells are multiple, and excellently
reviewed elsewhere [167].
The in vitro IC50 of salinomycin varies, depending on the source, cell type used and treatment
period, between 0.3 and 10 µM. Up-to-date, there is no comprehensive pharmacokinetic study of
salinomycin in animals or humans. Similar to the anti-parasitic drugs, salinomycin is normally
delivered orally, however this route is unacceptable for anticancer applications due to low
bioavailability and therefore resulting low blood and organ levels. It is also shown that after intravenous
injection in mice, salinomycin is rapidly metabolized [168] and therefore frequent injections/infusions
are likely necessary, though nothing is known regarding the anticancer activities and pharmacokinetics
of its metabolites. Prolonged daily injections of 10 mg/kg of salinomycin in mice grafted with
nasopharyngeal carcinoma showed no overt toxicity and resulted in a decrease in the tumor burden,
and also in reduced levels of LRP6 and β-catenin [164]. Another group has also reported no toxicity
and marked tumor reduction concomitant with decreased GSK3β phosphorylation in an osteosarcoma
xenograft model in response to 5 mg/kg salinomycin daily [162]. Treatment with 4 mg/kg salinomycin
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reduced tumor burden in an in vivo model of hepatoma. This also corresponded to a significant
shutdown of GSK3β phosphorylation with a concomitant β-catenin decrease [163].
Unfortunately, there is currently little knowledge of the toxicity and pharmacology of salinomycin
in humans, as it has never been approved for human use. However, in an uncontrolled clinical pilot
study employing salinomycin to treat several patients with various metastatic cancers, metastases
regression was observed; in another case of squamous cell carcinoma of the vulva, monotherapy
resulted in prolonged progression-free disease. Salinomycin was given at 200–250 µg/kg, which
corresponds to the initial concentration in blood plasma of ca. 15–20 µM, agreeing with the mouse
dose of 1–2 mg/kg. Acute side effects in all cases were minor and included tachycardia and mild
tremors with no observed long-term toxicity [169]. Since then however, there have been no further
reports of trials involving salinomycin.
4.2. Clofazimine
Our group recently linked the anti-cancer properties of the anti-leprosy drug clofazimine to the
inhibition of the WNT pathway. In this study, the library of FDA-approved drugs was screened in
silico to identify potential antagonists of the WNT-FZD interaction. Out of the selected higher-scored
potential candidates, clofazimine was one of four compounds, which demonstrated significant specific
inhibition of the WNT-pathway in vitro when using the TopFlash reporter assay. Despite bioinformatics
evidence, the drug was not able to inhibit the WNT-FZD interaction. Instead, it targets the WNT
pathway downstream of β-catenin and can inhibit proliferation of TNBC cells [170]. Other potential
mechanisms of anticancer effects of clofazimine might be an indirect stimulation of phospholipase A2,
resulting in the lysophospholipid-induced apoptotic death [171], or interference of the drug with the
respiratory chain [172].
Clofazimine has shown an anti-WNT effect with the IC50 in the low-µM range (~3 µM), which is
somewhat higher than the usual plasma levels of this drug for anti-leprosy treatment (0.5–1 µM) [173].
However the drug is extremely lipophilic and therefore has a propensity to accumulate in tissues
resulting in concentrations of 100–500 µM, which in this case is favourable for the antitumor
therapy [170]. While investigation of anti-WNT effects in vivo is now ongoing, these data help
to explain previous results of cancer inhibition shown in squamous hepatocellular carcinoma cell
cultures [171], in mammary cancer in vivo [174], and in lung cancer in vitro and in vivo [172].
A phase II study has claimed benefits of clofazimine for the indications of unresectable and
metastatic hepatocellular carcinoma, where 50% of the patients showed a response or disease
stabilization [175]. However, this could not be concluded for the advanced unresectable primary
hepatocellular carcinoma, when treated with clofazimine in combination with doxorubicin [176].
Altogether, these studies and the fact that clofazimine is generally considered a well-tolerated
and safe drug (its common side-effects include skin discoloration and rashes, palpitations and
enterophaties [175,177]) are encouraging for the future repositioning of clofazimine as an anticancer
drug directed against highly WNT-dependent tumors such as TNBC. A future challenge will be managing
and discovering the effect of clofazimine, when used at high doses for long-term oncology therapy.
4.3. Other Antimicrobials
Salinomycin and clofazimine are not the only antimicrobial drugs in the spotlight for repositioning
against WNT-dependent cancers. In this section we review three other compounds approved for
human use, which do not benefit from extensive records in scientific literature but have shown promise
for targeting the WNT pathway.
Tigecyclin, a tetracycline derivative, inhibits human cervical cancer cell growth in vitro and
in vitro, especially when combined with the well-known chemotherapeutic paclitaxel. It decreases
both cytoplasmic and nuclear levels of β-catenin and decreases transcription of the WNT-target genes,
while increasing the levels of AXIN1 [178].
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The antitumor antibiotic streptonigrin was in anticancer trials until 1977 but was discontinued
as the toxic effects outweighed therapeutic benefits. The drug’s original mechanism of action was
mostly due to the induction of DNA damage [179,180]. It has recently been demonstrated that the
anti-neoplastic effect might also be achieved through the inhibitory effects of streptonigrin on the
β-catenin/TCF complex formation with DNA. However, it seems that this drug has additional targets
since suppression of GSK3β phosphorylation and decrease in β-catenin were also observed [181].
Hexachlorophene, a disinfectant previously used as a bacteriostatic skin cleanser, has
demonstrated WNT/β-catenin pathway inhibition by promoting degradation of β-catenin through
the ubiquitin ligase SIAH1 in colon cancer cells and EBV-infected B-lymphoma, as well as inhibition of
cell proliferation in colon cancer cells [182,183].
5. Additional Selected Compounds
5.1. Metformin
Metformin was originally developed as an antidiabetic drug, stimulating the adenosine
monophosphate activated protein kinase (AMPK). It was approved by the FDA in 1995. The anticancer
effects of metformin have been demonstrated by population-based retrospective studies that reported a
decrease in the cancer incidence and a better cancer prognostic outcome in diabetic patients diagnosed
with cancer treated with metformin, in comparison to diabetics diagnosed with cancer while not
treated with metformin [184,185].
A recent study revealed that anti-proliferative actions of metformin are also associated with the
indirect inhibition of the WNT pathway. Surprisingly, its effects are mediated through its original
target—AMPK, which then employs the MTOR signaling pathway to promote the ubiquitination
and proteasomal degradation of DVL3, one of the principal WNT transducers [186]. This is very
encouraging as it means that the drug can be used at its normal dose to exert its anti-WNT effects,
and indeed the doses of metformin reported in the study corresponded to those found for AMPK
activation in human tissues [187]. However, AMPK is a multi-faceted target, acting not only through
the MTOR pathway, but also involved in regulation of the mRNA translation machinery [188]. In
addition, metformin’s activities may involve perturbations of tumor metabolism and may be mediated
by immunomodulatory mechanisms, sustaining the anticancer immune response [189]. Overall, the
anti-proliferative action of metformin in cancer cells has been shown in vitro against lung, pancreatic
and gastric cancers [190–192] and both in cell lines in and in preclinical models of hepatocellular
carcinoma and in ovarian CSCs [193,194].
As the discovery of the anticancer effect of metformin in 2013 was based on clinical data from
more than 5000 breast cancer patients (1013 out of them were taking metformin), the results are
essentially equivalent to those of a large-scale Phase III clinical trial. This, in combination with no
need to significantly escalate the dose or change the delivery route of the drug, expectedly sparked
immediate attention of clinicians to metformin. There are 55 clinical trials that have been launched
since then, testing the anticancer activity of metformin against a large diversity of cancers in various
phases with different endpoints. Any definitive results from these trials should be expected in a few
years from now and for details one may consider this excellent review [188].
5.2. Imatinib
Imatinib, known under the trade names of Gleevec/Glivec, is a tyrosine kinase inhibitor targeting
BCR/ABL, which is the primary target in chronic myeloid leukemia, and some receptor tyrosine
kinases (PDGFR, c-KIT) important in gastrointestinal stromal tumors [195]. Its tyrosine inhibitor
function has shown to also affect the WNT/β-catenin signaling in anaplastic thyroid carcinoma cells
in a c-ABL dependent manner. Imatinib-treated cells have reduced transcription of the WNT target
genes such as cyclin D1. Imatinib also reduced β-catenin levels, inducing its relocation from nucleus
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to the plasma membrane, decreasing cell invasiveness [196]. In colon cancer cells, imatinib has shown
similar effects indicating that it can be efficient against different WNT-dependent cancers [197].
5.3. Ethacrynic Acid
The WNT-inhibitory effects of the loop diuretic ethacrynic acid (EA) were first discovered
in a library screen containing 960 FDA approved drugs. EA inhibited the TopFlash reporter in a
dose-dependent manner and was further demonstrated by co-immunoprecipitation studies to target
LEF1 and destabilize formation of its complex with β-catenin [198]. In patient-derived chronic
lymphocytic leukaemia cells, EA reduced expression of the WNT-target genes such as fibronectin,
cyclin D1 and LEF1 [198]. Another study has additionally shown that treatment of myeloma cells with
EA results in decreased levels of β-catenin, which points toward existence of several inputs of this
drug in WNT signaling inhibition. In vivo EA alone has shown excellent promise and was able to
inhibit myeloma growth and prolong survival in mice more efficiently than lenalidomide, the drug
currently used in patients with multiple myeloma [199,200].
In humans the maximum dose of EA when administered by intravenous injection is 100 mg/day,
which results in plasma levels of around 30 µM [201]. This corresponds to the WNT inhibitory doses
used in the in vitro studies [198,199]. In mice, the oral dose of 450 µg/day should result in plasma
levels close to those in humans mentioned above, meaning that inhibition of the tumor growth may
also be feasible in humans, however no reports of such a study currently exist.
5.4. Riluzole
Several studies reported that in a significant number of melanoma cases the WNT ligand
responsible for the invasiveness and metastasis is non-canonical WNT5A which is known to suppress
canonical signaling and function through other branches of the WNT signaling [202]. This makes these
subtypes of melanoma the only known case of cancer which does not benefit from the elevated levels
of canonical WNT signaling. On the contrary, elevated β-catenin levels in corresponding models of the
disease have been associated with reduced cell proliferation and improved patient survival, which
are the result of induction of cell differentiation [203]. This prompted the screening aimed at finding
WNT pathway enhancers, in which the FDA-approved riluzole, a therapeutic for amyotrophic lateral
sclerosis, was identified. Further testing of riluzole on melanoma cells in vitro showed that it is indeed
able to enhance the ability of WNT3a to inhibit cell proliferation and promote pigmentation. In vivo
riluzole was able to decrease metastases formation in mouse models. The authors further identified
the glutamate receptor GRM1, a known indirect target of riluzole, to be a regulator of WNT/β-catenin
signaling, linking inhibition of GRM1 by the drug to enhancement of the WNT pathway [204]. Patients
with GRM1-positive metastatic melanoma were enrolled in a “Phase 0” clinical trial, preliminarily
assessing the effects of treatment with riluzole. The study has shown positive dynamics both in
regard of pathological responses and biomarkers (pERK and pAKT), favouring further studies in
this direction [205]. It should be noted that repositioning of positive WNT modulators is not only
attractive against melanoma, but can be extended into the fields of regenerative and anti-ageing
medicine where the WNT pathway is in charge of tissue renewal and may be employed to achieve
better outcomes [26,206].
6. Challenges and Future Directions for Repositioning WNT Inhibitors in Cancers
As we may conclude, search of the WNT pathway inhibitors among the existing drugs is an idea
which excites many minds in the broadly defined field of translational research. Many of them are
attracted by the fast-tracking of the results into the clinic, as well as by the usual sheer availability of the
mass-produced drug compounds and information on their various aspects such as solubility, metabolic
stability and toxicity. This work has already resulted in a considerable amount of promising results
reviewed here (Table 1 and Figure 1). However, use of the approved drugs is a double-edged sword,
and here we would like to discuss some of the emerging challenges and problems of this approach.
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Challenges of the first type are not unique for the WNT signaling but instead concern any attempts
to reposition an existing drug for a new purpose. These obstacles of general nature are as follows
(also see reviews [29,207]):
‚ Frequently, for a novel application the drug is required at a higher dose, for an extended treatment
period or with a different formulation as compared to the conventional indication in order to
demonstrate a significant effect. This may result in unexpected side effects, jeopardizing the
idea of the “fast tracking” of the compound due to necessity of a full-scale preclinical and
clinical investigation.
‚ Intellectual property difficulties due to multitude of patents.
‚ Drug-drug incompatibility: acceptable levels of adverse effects for one application might make
the compound useless or uncompetitive for another purpose, as well as incompatible with other
treatments for the purpose.
‚ Different legal statuses of the drug in various countries, e.g., dependence on the region where the
disease is widespread or on the socioeconomical status of the population.
‚ Multiple and controversial mechanisms of novel action, resulting from superposition of the
original drug mechanism with the novel one(s).
In addition to that, there are certain challenges, which are specific for drug repositioning for
targeting the WNT pathway in cancer:
‚ The WNT pathway is complex. Many components of the signaling are shared with other
pathways, generating cross-talks of varying intensities. Therefore, it is sometimes difficult to
clearly distinguish direct influence of the drug on the WNT pathway from its effects on the
intersecting pathways.
‚ Identification of the molecular target is a complicated process, and it is frequently omitted by
researchers. Out of the 16 drugs we reviewed here, only EA, suramin, sulindac, pyrvinium
pamoate and indomethacin were shown to directly affect identified components of the WNT
pathway. Additionally, metformin is known to affect WNT signaling via a cross-talk from its
original target AMPK. Delaying the unequivocal identification of the novel molecular target
makes it problematic to optimize the drug and evaluate of the scope of its anticancer applications.
It should be also noted that the WNT pathway is not exclusively employed during development
or overactivated in cancer. In adults many healthy tissues rely on it for renewal and homeostasis
maintenance, most notably the intestine, haematopoietic system, hair, bones and skin. Therefore one
might expect adverse reactions in all these organ systems, which has indeed been observed for many
WNT-targeting compounds upon attempts to push them into the clinics. The intestine seems to be the
most vulnerable in this regard, causing the failure of many anti-WNT agents. As examples, XAV939
and LGK974 result in severe intestinal toxicity in mice, while OMP18RP induces abdominal pain,
constipation and diarrhea in patients [208,209].
An interesting and promising direction is the modification of approved drugs for novel diseases.
In general, this approach dictates the necessity of full-scale de novo trials, however it still might be
considered a future path in drug development. Although the data accumulated for the parent drug
cannot be used directly, they will still serve as a strong guide and facilitator in the drug development
process. Moreover, frequently there are libraries of the drug derivatives used during the development
of the original compound, already available for testing. Efficacy of novel derivatives may allow to
overcome many problems we described above for parent molecules, such as multiplicity of mechanisms,
dose elevations, and not to forget the hurdles involving the intellectual property.
Of the drugs reviewed here, only some were subjected to medicinal chemistry optimization.
Derivatives of niclosamide were synthesized with better metabolic stability without compromising
WNT inhibition [210]. In another study, >40 ethacrynic acid derivatives were reported, the best ones
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with enhanced WNT inhibitory action were further found to inhibit growth of chronic lymphocytic
leukaemia cells [211]. A salinomycin-based drug VS-507 is part of the research portfolio of Verastat, a
company whose main focus is the development of anti-CSC therapies [169]. Additional noteworthy
attempts to improve salinomycin aimed at reducing its toxicity [212] and improving its potency [213].
There are also reports on derivatives of NSAIDs lacking COX inhibition and showing inhibitory effects
on cancer cell lines and tumors in rodent models [57,214,215]. Other derivatization attempts were
aimed at overcoming the side effects of NSAIDs, producing nitric oxide releasing aspirin (NO-ASA) and
phospho-sulindac, with improved potency and lower gastro-intestinal adverse reactions in mice [216,217].
7. Concluding Remarks
WNT signaling is one of the developmental pathways [216], whose reactivation in many
adult tissues underlies oncogenic transformation. Although no drugs against this pathway are yet
on the market nor even in advanced clinical trials, the demand for such drugs is urgent. First
medications targeting the hedgehog signaling pathway—another embryogenic pathway responsible
for various types of adult cancers, previously also evading drug discovery efforts, have recently
been approved [26,217]. This success should inspire researchers developing the anti-WNT agents to
continue their quest. Clearly, all possible drug discovery approaches (antibodies, de novo screening
of synthetic small molecules, rational drug design and in silico screening, natural products, etc.)
are welcome in this task [218]. Repositioning of existing drugs for the new indication of treating
WNT-dependent cancers is one of such avenues. Examples discussed in this review illustrate the
achievements and remaining hurdles on this path, and reflect our cautious optimism that continuation
of it may eventually ensure appearance of first-in-class medicines to treat devastating diseases hijacking
the WNT pathway for their progression.
Acknowledgments: This work was supported the Swiss Cancer League grant KFS-2978-08-2012 to V.L.K. and the
InnoPACTT/FIT grant 2607 5283 to A.K. and V.L.K. Publishing costs are covered by the University of Lausanne.
Author Contributions: V.L.K. designed, K.A. and H.V.S. wrote, and A.K. and V.L.K. corrected the review article.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Nusse, R. Wnt signaling in disease and in development. Cell Res. 2005, 15, 28–32. [CrossRef] [PubMed]
2. Krausova, M.; Korinek, V. Wnt signaling in adult intestinal stem cells and cancer. Cell. Signal. 2014, 26,
570–579. [CrossRef] [PubMed]
3. Malhotra, S.; Kincade, P.W. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis.
Cell Stem Cell 2009, 4, 27–36. [CrossRef] [PubMed]
4. Whyte, J.L.; Smith, A.A.; Helms, J.A. Wnt signaling and injury repair. Cold Spring Harb. Perspect. Biol. 2012.
[CrossRef] [PubMed]
5. Polakis, P. Drugging Wnt signaling in cancer. EMBO J. 2012, 31, 2737–2746. [CrossRef] [PubMed]
6. Solis, G.P.; Lüchtenborg, A.M.; Katanaev, V.L. Wnt secretion and gradient formation. Int. J. Mol. Sci. 2013, 14,
5130–5145. [CrossRef] [PubMed]
7. Koval, A.; Katanaev, V.L. Wnt3a stimulation elicits G-protein-coupled receptor properties of mammalian
Frizzled proteins. Biochem. J. 2011, 433, 435–440. [CrossRef] [PubMed]
8. Schulte, G. Frizzleds and Wnt/β-catenin signaling—The black box of ligand-receptor selectivity, complex
stoichiometry and activation kinetics. Eur. J. Pharmacol. 2015, 763, 191–195. [CrossRef] [PubMed]
9. Komiya, Y.; Habas, R. Wnt signal transduction pathways. Organogenesis 2008, 4, 68–75. [CrossRef] [PubMed]
10. Giles, R.H.; van Es, J.H.; Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys.
Acta Rev. Cancer 2003, 1653, 1–24. [CrossRef]
11. Egger-Adam, D. Trimeric G protein-dependent signaling by Frizzled receptors in animal development.
Front. Biosci. 2008, 13, 4740–4755. [CrossRef] [PubMed]
12. Gao, C.; Chen, Y.G. Dishevelled: The hub of Wnt signaling. Cell. Signal. 2010, 22, 717–727. [CrossRef]
[PubMed]
Cancers 2016, 8, 66 17 of 27
13. Cliffe, A.; Hamada, F.; Bienz, M. A role of Dishevelled in relocating Axin to the plasma membrane during
wingless signaling. Curr. Biol. 2003, 13, 960–966. [CrossRef]
14. Egger-Adam, D.; Katanaev, V.L. The trimeric G protein Go inflicts a double impact on Axin in the
Wnt/Frizzled signaling pathway. Dev. Dyn. 2010, 239, 168–183. [CrossRef] [PubMed]
15. Kimelman, D.; Xu, W. β-catenin destruction complex: Insights and questions from a structural perspective.
Oncogene 2006, 25, 7482–7491. [CrossRef] [PubMed]
16. Willert, K.; Jones, K.A. Wnt signaling: Is the party in the nucleus? Genes Dev. 2006, 20, 1394–1404. [CrossRef]
[PubMed]
17. Liao, D.J.; Thakur, A.; Wu, J.; Biliran, H.; Sarkar, F.H. Perspectives on c-Myc, Cyclin D1, and their interaction
in cancer formation, progression, and response to chemotherapy. Crit. Rev. Oncog. 2007, 13, 93–158.
[CrossRef] [PubMed]
18. Prosperi, J.R.; Luu, H.H.; Goss, K.H. Dysregulation of the Wnt pathway in solid tumors. In Targeting the Wnt
Pathway in Cancer; Goss, H.K., Kahn, M., Eds.; Springer: New York, NY, USA, 2011; pp. 81–128.
19. Fearnhead, N.S.; Britton, M.P.; Bodmer, W.F. The ABC of APC. Hum. Mol. Genet. 2001, 10, 721–733. [CrossRef]
[PubMed]
20. Merle, P.; de la Monte, S.; Kim, M.; Herrmann, M.; Tanaka, S.; von dem Bussche, A.; Kew, M.C.; Trepo, C.;
Wands, J.R. Functional consequences of Frizzled-7 receptor overexpression in human hepatocellular
carcinoma. Gastroenterology 2004, 127, 1110–1122. [CrossRef] [PubMed]
21. Yang, L.; Wu, X.; Wang, Y.; Zhang, K.; Wu, J.; Yuan, Y.C.; Deng, X.; Chen, L.; Kim, C.C.; Lau, S.; et al. FZD7 has
a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011, 30, 4437–4446. [CrossRef]
[PubMed]
22. Wissmann, C.; Wild, P.J.; Kaiser, S.; Roepcke, S.; Stoehr, R.; Woenckhaus, M.; Kristiansen, G.; Hsieh, J.C.;
Hofstaedter, F.; Hartmann, A.; et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate,
breast, lung, and bladder cancer. J. Pathol. 2003, 201, 204–212. [CrossRef] [PubMed]
23. Takahashi-Yanaga, F.; Kahn, M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells?
Clin. Cancer Res. 2010, 16, 3153–3162. [CrossRef] [PubMed]
24. Curtin, J.C.; Lorenzi, M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget
2010, 1, 552–566. [CrossRef] [PubMed]
25. Jordan, C.T.; Guzman, M.L.; Noble, M. Cancer stem cells. N. Engl. J. Med. 2006, 355, 1253–1261. [CrossRef]
[PubMed]
26. Blagodatski, A.; Poteryaev, D.; Katanaev, V.L. Targeting the Wnt pathways for therapies. Mol. Cell. Ther.
2014. [CrossRef] [PubMed]
27. Paul, S.M.; Mytelka, D.S.; Dunwiddie, C.T.; Persinger, C.C.; Munos, B.H.; Lindborg, S.R.; Schacht, A.L. How
to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 2010,
9, 203–214. [PubMed]
28. Hay, M.; Thomas, D.W.; Craighead, J.L.; Economides, C.; Rosenthal, J. Clinical development success rates for
investigational drugs. Nat. Biotechnol. 2014, 32, 40–51. [CrossRef] [PubMed]
29. Ashburn, T.T.; Thor, K.B. Drug repositioning: Identifying and developing new uses for existing drugs.
Nat. Rev. Drug Discov. 2004, 3, 673–683. [CrossRef] [PubMed]
30. Shim, J.S.; Liu, J.O. Recent advances in drug repositioning for the discovery of new anticancer drugs.
Int. J. Biol. Sci. 2014, 10, 654–663. [CrossRef] [PubMed]
31. Guidance for Industry Expedited Programs for Serious Conditions—Drugs and Biologics. Available online:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM358301.pdf (accessed on 26 June 2016).
32. Day, R.O.; Graham, G.G. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ 2013. [CrossRef]
33. Gurpinar, E.; Grizzle, W.E.; Piazza, G.A. NSAIDs inhibit tumorigenesis, but how? Clin.Cancer Res. 2014, 20,
1104–1113. [CrossRef] [PubMed]
34. Thun, M.J.; Henley, S.J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic,
pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94, 252–266. [CrossRef] [PubMed]
35. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009,
302, 649–658. [CrossRef] [PubMed]
Cancers 2016, 8, 66 18 of 27
36. Dube, C.; Rostom, A.; Lewin, G.; Tsertsvadze, A.; Barrowman, N.; Code, C.; Sampson, M.; Moher, D. The use
of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive
services task force. Ann. Int. Med. 2007, 146, 365–375. [CrossRef] [PubMed]
37. Rothwell, P.M.; Fowkes, F.G.R.; Belch, J.F.F.; Ogawa, H.; Warlow, C.P.; Meade, T.W. Effect of daily aspirin on
long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet
2011, 377, 31–41. [CrossRef]
38. Jacobs, E.J.; Thun, M.J.; Bain, E.B.; Rodriguez, C.; Henley, S.J.; Calle, E.E. A large cohort study of long-term
daily use of adult-strength aspirin and cancer incidence. J. Natl. Cancer Inst. 2007, 99, 608–615. [CrossRef]
[PubMed]
39. Khuder, S.A.; Mutgi, A.B. Breast cancer and NSAIDs use: A meta-analysis. Br. J. Cancer 2001, 84, 1188–1192.
[CrossRef] [PubMed]
40. Yiannakopoulou, E. Aspirin and NSAIDs for breast cancer chemoprevention. Eur. J. Cancer Prev. 2015, 24,
416–421. [CrossRef] [PubMed]
41. McCormack, V.A.; Hung, R.J.; Brenner, D.R.; Bickeboller, H.; Rosenberger, A.; Muscat, J.E.; Lazarus, P.;
Tjonneland, A.; Friis, S.; Christiani, D.C.; et al. Aspirin and NSAID use and lung cancer risk: A pooled
analysis in the international lung cancer consortium (ilcco). Cancer Causes Control 2011, 22, 1709–1720.
[CrossRef] [PubMed]
42. Corley, D.A.; Kerlikowske, K.; Verma, R.; Buffler, P. Protective association of aspirin/ NSAIDs and esophageal
cancer: A systematic review and meta-analysis. Gastroenterology 2003, 124, 47–56. [CrossRef] [PubMed]
43. Vidal, A.C.; Howard, L.E.; Moreira, D.M.; Castro-Santamaria, R.; Andriole, G.L.; Freedland, S.J. Aspirin,
nsaids, and risk of prostate cancer: Results from the reduce study. Clin. Cancer Res. 2015, 21, 756–762.
[CrossRef] [PubMed]
44. Daugherty, S.E.; Pfeiffer, R.M.; Sigurdson, A.J.; Hayes, R.B.; Leitzmann, M.; Schatzkin, A.; Hollenbeck, A.R.;
Silverman, D.T. Nonsteroidal antiinflammatory drugs and bladder cancer: A pooled analysis. Am. J. Epidemiol.
2011, 173, 721–730. [CrossRef] [PubMed]
45. Zhang, Y.P.; Wan, Y.D.; Sun, Y.L.; Li, J.; Zhu, R.T. Aspirin might reduce the incidence of pancreatic cancer: A
meta-analysis of observational studies. Sci. Rep. 2015. [CrossRef] [PubMed]
46. Castellone, M.D.; Teramoto, H.; Williams, B.O.; Druey, K.M.; Gutkind, J.S. Prostaglandin E2 promotes colon
cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310, 1504–1510. [CrossRef]
[PubMed]
47. Shao, J.; Jung, C.; Liu, C.; Sheng, H. Prostaglandin E2 stimulates the beta-catenin/T cell factor-dependent
transcription in colon cancer. J. Biol. Chem. 2005, 280, 26565–26572. [CrossRef] [PubMed]
48. Oshima, M.; Dinchuk, J.E.; Kargman, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.;
Taketo, M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of
cyclooxygenase 2 (COX-2). Cell 1996, 87, 803–809. [CrossRef]
49. Sheng, H.; Shao, J.; Kirkland, S.C.; Isakson, P.; Coffey, R.J.; Morrow, J.; Beauchamp, R.D.; DuBois, R.N.
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 1997,
99, 2254–2259. [CrossRef] [PubMed]
50. Boon, E.M.J.; Keller, J.J.; Wormhoudt, T.A.M.; Giardiello, F.M.; Offerhaus, G.J.A.; van der Neut, R.; Pals, S.T.
Sulindac targets nuclear β-catenin accumulation and Wnt signaling in adenomas of patients with familial
adenomatous polyposis and in human colorectal cancer cell lines. Br. J. Cancer 2004, 90, 224–229. [CrossRef]
[PubMed]
51. Han, A.; Song, Z.; Tong, C.; Hu, D.; Bi, X.; Augenlicht, L.H.; Yang, W. Sulindac suppresses β-catenin
expression in human cancer cells. Eur. J. Pharmacol. 2008, 583, 26–31. [CrossRef] [PubMed]
52. Tinsley, H.N.; Gary, B.D.; Keeton, A.B.; Lu, W.; Li, Y.; Piazza, G.A. Inhibition of PDE5 by sulindac sulfide
selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human
breast tumor cells. Cancer Prev. Res. 2011, 4, 1275–1284. [CrossRef] [PubMed]
53. Steinert, G.; Oancea, C.; Roos, J.; Hagemeyer, H.; Maier, T.; Ruthardt, M.; Puccetti, E. Sulindac sulfide reverses
aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RAR and
PLZF/RARalpha. PLoS ONE 2011, 6, e22540. [CrossRef] [PubMed]
54. Lu, W.; Tinsley, H.N.; Keeton, A.; Qu, Z.; Piazza, G.A.; Li, Y. Suppression of Wnt/β-catenin signaling inhibits
prostate cancer cell proliferation. Eur. J. Pharmacol. 2009, 602, 8–14. [CrossRef] [PubMed]
Cancers 2016, 8, 66 19 of 27
55. Lee, H.J.; Wang, N.X.; Shi, D.L.; Zheng, J.J. Sulindac inhibits canonical Wnt signaling by blocking the PDZ
domain of the protein Dishevelled. Angew. Chem. 2009, 48, 6448–6452. [CrossRef] [PubMed]
56. Li, N.; Xi, Y.; Tinsley, H.N.; Gurpinar, E.; Gary, B.D.; Zhu, B.; Li, Y.; Chen, X.; Keeton, A.B.; Abadi, A.H.; et al.
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress
Wnt/β-catenin signaling. Mol. Cancer Ther. 2013, 12, 1848–1859. [CrossRef] [PubMed]
57. Piazza, G.A.; Alberts, D.S.; Hixson, L.J.; Paranka, N.S.; Li, H.; Finn, T.; Bogert, C.; Guillen, J.M.; Brendel, K.;
Gross, P.H.; et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without
reducing prostaglandin levels. Cancer Res. 1997, 57, 2909–2915. [PubMed]
58. Stein, U.; Arlt, F.; Smith, J.; Sack, U.; Herrmann, P.; Walther, W.; Lemm, M.; Fichtner, I.; Shoemaker, R.H.;
Schlag, P.M. Intervening inβ-catenin signaling by sulindac inhibits s100a4-dependent colon cancer metastasis.
Neoplasia 2011, 13, 131–144. [CrossRef] [PubMed]
59. Xie, G.; Nie, T.; Mackenzie, G.G.; Sun, Y.; Huang, L.; Ouyang, N.; Alston, N.; Zhu, C.; Murray, O.T.;
Constantinides, P.P.; et al. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the
effect of difluoromethylornithine. Br. J. Pharmacol. 2012, 165, 2152–2166. [CrossRef] [PubMed]
60. McEntee, M.F.; Chiu, C.H.; Whelan, J. Relationship of beta-catenin and Bcl-2 expression to sulindac-induced
regression of intestinal tumors in min mice. Carcinogenesis 1999, 20, 635–640. [CrossRef] [PubMed]
61. Brown, W.A.; Skinner, S.A.; Vogiagis, D.; O’Brien, P.E. Inhibition of β-catenin translocation in rodent
colorectal tumors: A novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in
colorectal cancer. Dig. Dis. Sci. 2001, 46, 2314–2321. [CrossRef] [PubMed]
62. Kune, G.A.; Kune, S.; Watson, L.F. Colorectal cancer risk, chronic illnesses, operations, and medications:
Case control results from the melbourne colorectal cancer study. Cancer Res. 1988, 48, 4399–4404. [CrossRef]
[PubMed]
63. Elwood, P.C.; Gallagher, A.M.; Duthie, G.G.; Mur, L.A.J.; Morgan, G. Aspirin, salicylates, and cancer. Lancet
2009, 373, 1301–1309. [CrossRef]
64. Dihlmann, S.; Siermann, A.; von Knebel Doeberitz, M. The nonsteroidal anti-inflammatory drugs aspirin
and indomethacin attenuate β-catenin/TCF-4 signaling. Oncogene 2001, 20, 645–653. [CrossRef] [PubMed]
65. Dihlmann, S.; Klein, S.; Doeberitz, M.V. Reduction of beta-catenin/T-cell transcription factor signaling
by aspirin and indomethacin is caused by an increased stabilization of phosphorylated β-catenin.
Mol. Cancer Ther. 2003, 2, 509–516. [PubMed]
66. Bos, C.L.; Kodach, L.L.; van den Brink, G.R.; Diks, S.H.; van Santen, M.M.; Richel, D.J.; Peppelenbosch, M.P.;
Hardwick, J.C. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2a.
Oncogene 2006, 25, 6447–6456. [CrossRef] [PubMed]
67. Ratcliffe, M.J.; Itoh, K.; Sokol, S.Y. A positive role for the PP2A catalytic subunit in Wnt signal transduction.
J. Biol. Chem. 2000, 275, 35680–35683. [CrossRef] [PubMed]
68. Gala, M.K.; Chan, A.T. Molecular pathways: Aspirin and Wnt signaling-a molecularly targeted approach to
cancer prevention and treatment. Clin.Cancer Res. 2015, 21, 1543–1548. [CrossRef] [PubMed]
69. Mahmoud, N.N.; Dannenberg, A.J.; Mestre, J.; Bilinski, R.T.; Churchill, M.R.; Martucci, C.; Newmark, H.;
Bertagnolli, M.M. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery
1998, 124, 225–231. [CrossRef]
70. Alfonso, L.; Ai, G.; Spitale, R.C.; Bhat, G.J. Molecular targets of aspirin and cancer prevention. Br. J. Cancer
2014, 111, 61–67. [CrossRef] [PubMed]
71. Langley, R.E. Clinical evidence for the use of aspirin in the treatment of cancer. Ecancermedicalscience 2013.
[CrossRef]
72. Stark, L.A.; Reid, K.; Sansom, O.J.; Din, F.V.; Guichard, S.; Mayer, I.; Jodrell, D.I.; Clarke, A.R.; Dunlop, M.G.
Aspirin activates the NF-kappaB signaling pathway and induces apoptosis in intestinal neoplasia in
twoin vivo models of human colorectal cancer. Carcinogenesis 2007, 28, 968–976. [CrossRef] [PubMed]
73. Din, F.V.; Theodoratou, E.; Farrington, S.M.; Tenesa, A.; Barnetson, R.A.; Cetnarskyj, R.; Stark, L.;
Porteous, M.E.; Campbell, H.; Dunlop, M.G. Effect of aspirin and NSAIDs on risk and survival from
colorectal cancer. Gut 2010, 59, 1670–1679. [CrossRef] [PubMed]
74. Cerletti, C.; Bonati, M.; del Maschio, A.; Galletti, F.; Dejana, E.; Tognoni, G.; de Gaetano, G. Plasma levels
of salicylate and aspirin in healthy volunteers: Relevance to drug interaction on platelet function. J. Lab.
Clin. Med. 1984, 103, 869–877. [PubMed]
Cancers 2016, 8, 66 20 of 27
75. Grosser, T.; Smyth, E.; FitzGerald, G.A. Chapter 34. Anti-inflammatory, antipyretic, and analgesic agents;
pharmacotherapy of gout. In Goodman & Amp; Gilman’s the Pharmacological Basis of Therapeutics, 12e;
Brunton, L.L., Chabner, B.A., Knollmann, B.C., Eds.; The McGraw-Hill Companies: New York, NY, USA, 2011.
76. Smith, M.L.; Hawcroft, G.; Hull, M.A. The effect of non-steroidal anti-inflammatory drugs on human
colorectal cancer cells: Evidence of different mechanisms of action. Eur. J. Cancer 2000, 36, 664–674. [CrossRef]
77. Kapitanovic, S.; Cacev, T.; Antica, M.; Kralj, M.; Cavric, G.; Pavelic, K.; Spaventi, R. Effect of indomethacin
on E-cadherin and beta-catenin expression in HT-29 colon cancer cells. Exp. Mol. Pathol. 2006, 80, 91–96.
[CrossRef] [PubMed]
78. Hawcroft, G.; D’Amico, M.; Albanese, C.; Markham, A.F.; Pestell, R.G.; Hull, M.A. Indomethacin induces
differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal
cancer cells. Carcinogenesis 2002, 23, 107–114. [CrossRef] [PubMed]
79. Brown, W.A.; Skinner, S.A.; Malcontenti-Wilson, C.; Vogiagis, D.; O’Brien, P.E. Non-steroidal
anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal
cancer in a dmh rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 2001, 48, 660–666.
[CrossRef] [PubMed]
80. Guissou, P.; Cuisinaud, G.; Legheand, J.; Sassard, J. Chronopharmacokinetics of indomethacin in rats.
Arzneim. Forsch. 1987, 37, 1034–1037.
81. Sakoguchi-Okada, N.; Takahashi-Yanaga, F.; Fukada, K.; Shiraishi, F.; Taba, Y.; Miwa, Y.; Morimoto, S.;
Iida, M.; Sasaguri, T. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in
human colon cancer cells. Biochem. Pharmacol. 2007, 73, 1318–1329. [CrossRef] [PubMed]
82. Takahashi-Yanaga, F.; Yoshihara, T.; Jingushi, K.; Miwa, Y.; Morimoto, S.; Hirata, M.; Sasaguri, T.
Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells. Biochem. Biophys.
Res. Commun. 2008, 377, 1185–1190. [CrossRef] [PubMed]
83. Tuynman, J.B.; Vermeulen, L.; Boon, E.M.; Kemper, K.; Zwinderman, A.H.; Peppelenbosch, M.P.; Richel, D.J.
Cyclooxygenase-2 inhibition inhibits c-met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008,
68, 1213–1220. [CrossRef] [PubMed]
84. Sareddy, G.R.; Kesanakurti, D.; Kirti, P.B.; Babu, P.P. Nonsteroidal anti-inflammatory drugs diclofenac and
celecoxib attenuates Wnt/β-catenin/TCF signaling pathway in human glioblastoma cells. Neurochem. Res.
2013, 38, 2313–2322. [CrossRef] [PubMed]
85. Behari, J.; Zeng, G.; Otruba, W.; Thompson, M.D.; Muller, P.; Micsenyi, A.; Sekhon, S.S.; Leoni, L.; Monga, S.P.
R-etodolac decreases β-catenin levels along with survival and proliferation of hepatoma cells. J. Hepatol.
2007, 46, 849–857. [CrossRef] [PubMed]
86. Xia, J.J.; Pei, L.B.; Zhuang, J.P.; Ji, Y.; Xu, G.P.; Zhang, Z.P.; Li, N.; Yan, J.L. Celecoxib inhibits
β-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J. Int. Med. Res. 2010, 38,
1294–1304. [CrossRef] [PubMed]
87. Deng, Y.; Su, Q.; Mo, J.; Fu, X.; Zhang, Y.; Lin, E.H. Celecoxib downregulates CD133 expression through
inhibition of the Wnt signaling pathway in colon cancer cells. Cancer Invest. 2013, 31, 97–102. [CrossRef]
[PubMed]
88. Dharmapuri, G.; Doneti, R.; Philip, G.H.; Kalle, A.M. Celecoxib sensitizes imatinib-resistant K562 cells to
imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways.
Leuk. Res. 2015, 39, 696–701. [CrossRef] [PubMed]
89. Yamada, Y.; Yoshimi, N.; Hirose, Y.; Hara, A.; Shimizu, M.; Kuno, T.; Katayama, M.; Qiao, Z.; Mori, H.
Suppression of occurrence and advancement of β-catenin-accumulated crypts, possible premalignant lesions
of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. Jpn. J. Cancer Res. Gann 2001, 92, 617–623.
[CrossRef] [PubMed]
90. Zhang, S.; Da, L.; Yang, X.; Feng, D.; Yin, R.; Li, M.; Zhang, Z.; Jiang, F.; Xu, L. Celecoxib potentially inhibits
metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated beta-catenin
pathway. Toxicol. Lett. 2014, 225, 201–207. [CrossRef] [PubMed]
91. Park, W.; Oh, Y.T.; Han, J.H.; Pyo, H. Antitumor enhancement of celecoxib, a selective cyclooxygenase-2
inhibitor, in a lewis lung carcinoma expressing cyclooxygenase-2. J. Exp. Clin. Cancer Res. 2008. [CrossRef]
[PubMed]
Cancers 2016, 8, 66 21 of 27
92. Yoshinaka, R.; Shibata, M.A.; Morimoto, J.; Tanigawa, N.; Otsuki, Y. Cox-2 inhibitor celecoxib suppresses
tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res. 2006, 26, 4245–4254.
[PubMed]
93. Paulson, S.K.; Zhang, J.Y.; Breau, A.P.; Hribar, J.D.; Liu, N.W.; Jessen, S.M.; Lawal, Y.M.; Cogburn, J.N.;
Gresk, C.J.; Markos, C.S.; et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib
in rats. Drug Metab. Dispos. Biol. Fate Chem. 2000, 28, 514–521. [PubMed]
94. Steinbach, G.; Lynch, P.M.; Phillips, R.K.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.;
Saunders, B.; Shen, Y.; Fujimura, T.; et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial
adenomatous polyposis. N. Engl. J. Med. 2000, 342, 1946–1952. [CrossRef] [PubMed]
95. Katz, M. Anthelmintics. Drugs 1977, 13, 124–136. [CrossRef] [PubMed]
96. Li, R.; Hu, Z.; Sun, S.-Y.; Chen, Z.G.; Owonikoko, T.K.; Sica, G.L.; Ramalingam, S.S.; Curran, W.J.; Khuri, F.R.;
Deng, X. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small
cell lung cancer. Mol. Cancer Ther. 2013, 12, 2200–2212. [CrossRef] [PubMed]
97. Jin, Y.; Lu, Z.; Ding, K.; Li, J.; Du, X.; Chen, C.; Sun, X.; Wu, Y.; Zhou, J.; Pan, J. Antineoplastic mechanisms
of niclosamide in acute myelogenous leukemia stem cells: Inactivation of the NF-kappaB pathway and
generation of reactive oxygen species. Cancer Res. 2010, 70, 2516–2527. [CrossRef] [PubMed]
98. Tomizawa, M.; Shinozaki, F.; Motoyoshi, Y.; Sugiyama, T.; Yamamoto, S.; Sueishi, M.; Yoshida, T. Niclosamide
suppresses hepatoma cell proliferation via the Wnt pathway. Onco Targets Ther. 2013, 6, 1685–1693. [CrossRef]
[PubMed]
99. Satoh, K.; Zhang, L.; Zhang, Y.; Chelluri, R.; Boufraqech, M.; Nilubol, N.; Patel, D.; Shen, M.; Kebebew, E.
Identification of niclosamide as a novel anticancer agent for adrenocortical carcinoma. Clin. Cancer Res. 2016.
[CrossRef] [PubMed]
100. Arend, R.C.; Londoño-Joshi, A.I.; Samant, R.S.; Li, Y.; Conner, M.; Hidalgo, B.; Alvarez, R.D.; Landen, C.N.;
Straughn, J.M.; Buchsbaum, D.J. Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target
for ovarian cancer. Gynecol. Oncol. 2014, 134, 112–120. [CrossRef] [PubMed]
101. Wieland, A.; Trageser, D.; Gogolok, S.; Reinartz, R.; Höfer, H.; Keller, M.; Leinhaas, A.; Schelle, R.;
Normann, S.; Klaas, L. Anticancer effects of niclosamide in human glioblastoma. Clin. Cancer Res. 2013, 19,
4124–4136. [CrossRef] [PubMed]
102. Pan, J.-X.; Ding, K.; Wang, C.-Y. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity
by blocking multiple signaling pathways of cancer stem cells. Chin. J. Cancer 2012, 31, 178–184. [CrossRef]
[PubMed]
103. Londoño-Joshi, A.I.; Arend, R.C.; Aristizabal, L.; Lu, W.; Samant, R.S.; Metge, B.J.; Hidalgo, B.; Grizzle, W.E.;
Conner, M.; Forero-Torres, A. Effect of niclosamide on basal-like breast cancers. Mol. Cancer Ther. 2014, 13,
800–811. [CrossRef] [PubMed]
104. Lu, W.; Lin, C.; Roberts, M.J.; Waud, W.R.; Piazza, G.A.; Li, Y. Niclosamide suppresses cancer cell growth by
inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway. PLoS ONE 2011, 6,
e29290. [CrossRef] [PubMed]
105. Chen, M.; Wang, J.; Lu, J.; Bond, M.C.; Ren, X.-R.; Lyerly, H.K.; Barak, L.S.; Chen, W. The anti-helminthic
niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009, 48, 10267–10274. [CrossRef] [PubMed]
106. Osada, T.; Chen, M.; Yang, X.Y.; Spasojevic, I.; Vandeusen, J.B.; Hsu, D.; Clary, B.M.; Clay, T.M.; Chen, W.;
Morse, M.A.; et al. Anti-helminth compound niclosamide downregulates Wnt signaling and elicits antitumor
responses in tumors with activating APC mutations. Cancer Res. 2011, 71, 4172–4182. [CrossRef] [PubMed]
107. Wang, A.M.; Ku, H.H.; Liang, Y.C.; Chen, Y.C.; Hwu, Y.M.; Yeh, T.S. The autonomous notch signal pathway
is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J. Cell. Biochem. 2009,
106, 682–692. [CrossRef] [PubMed]
108. Fonseca, B.D.; Diering, G.H.; Bidinosti, M.A.; Dalal, K.; Alain, T.; Balgi, A.D.; Forestieri, R.; Nodwell, M.;
Rajadurai, C.V.; Gunaratnam, C. Structure-activity analysis of niclosamide reveals potential role for
cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem.
2012, 287, 17530–17545. [CrossRef] [PubMed]
109. Ye, T.; Xiong, Y.; Yan, Y.; Xia, Y.; Song, X.; Liu, L.; Li, D.; Wang, N.; Zhang, L.; Zhu, Y.; et al. The anthelmintic
drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast
cancer model. PLoS ONE 2014, 9, e85887. [CrossRef] [PubMed]
Cancers 2016, 8, 66 22 of 27
110. Andrews, P.; Thyssen, J.; Lorke, D. The biology and toxicology of molluscicides, bayluscide. Pharmacol. Ther.
1982, 19, 245–295. [CrossRef]
111. Voogd, T.E.; Vansterkenburg, E.L.; Wilting, J.; Janssen, L.H. Recent research on the biological activity of
suramin. Pharmacol. Rev. 1993, 45, 177–203. [PubMed]
112. Babokhov, P.; Sanyaolu, A.O.; Oyibo, W.A.; Fagbenro-Beyioku, A.F.; Iriemenam, N.C. A current analysis of
chemotherapy strategies for the treatment of human african trypanosomiasis. Pathog. Glob. Health 2013, 107,
242–252. [CrossRef] [PubMed]
113. Taylor, C.W.; Lui, R.; Fanta, P.; Salmon, S.E. Effects of suramin on in vitro growth of fresh human tumors.
J. Natl. Cancer Inst. 1992, 84, 489–494. [CrossRef] [PubMed]
114. Larsen, A.K. Suramin: An anticancer drug with unique biological effects. Cancer Chemother. Pharmacol. 1993,
32, 96–98. [CrossRef] [PubMed]
115. Li, H.; Li, H.; Qu, H.; Zhao, M.; Yuan, B.; Cao, M.; Cui, J. Suramin inhibits cell proliferation in ovarian
and cervical cancer by downregulating heparanase expression. Cancer Cell Int. 2015, 15, 1–11. [CrossRef]
[PubMed]
116. Coffey, R.J., Jr.; Leof, E.B.; Shipley, G.D.; Moses, H.L. Suramin inhibition of growth factor receptor binding
and mitogenicity in akr-2b cells. J. Cell. Physiol. 1987, 132, 143–148. [CrossRef] [PubMed]
117. Pesenti, E.; Sola, F.; Mongelli, N.; Grandi, M.; Spreafico, F. Suramin prevents neovascularisation and tumour
growth through blocking of basic fibroblast growth factor activity. Br. J. Cancer 1992, 66, 367–372. [CrossRef]
[PubMed]
118. Waltenberger, J.; Mayr, U.; Frank, H.; Hombach, V. Suramin is a potent inhibitor of vascular endothelial
growth factor. A contribution to the molecular basis of its antiangiogenic action. J. Mol. Cell. Cardiol. 1996,
28, 1523–1529. [CrossRef] [PubMed]
119. Rideout, D.C.; Bustamante, A.; Patel, R.; Henderson, G.B. Suramin sodium: Pronounced effects on
methotrexate transport and anti-folate activity in cultured tumor cells. Int. J. Cancer 1995, 61, 840–847.
[CrossRef] [PubMed]
120. Koval, A.; Ahmed, K.; Katanaev, V.L. Inhibition of Wnt signaling and breast tumour growth by the
multi-purpose drug suramin through suppression of heterotrimeric G proteins and Wnt endocytosis.
Biochem. J. 2016, 473, 371–381. [CrossRef] [PubMed]
121. Koval, A.; Katanaev, V.L. Platforms for high-throughput screening of Wnt/Frizzled antagonists.
Drug Discov. Today 2012, 17, 1316–1322. [CrossRef] [PubMed]
122. Katanaev, V.L. Prospects of targeting Wnt signaling in cancer. J. Pharmacol. Toxicol. Res. 2014, 1, 1–3.
123. Koval, A.; Purvanov, V.; Egger-Adam, D.; Katanaev, V.L. Yellow submarine of the Wnt/Frizzled signaling:
Submerging from the G protein harbor to the targets. Biochem. Pharmacol. 2011, 82, 1311–1319. [CrossRef]
[PubMed]
124. Purvanov, V.; Koval, A.; Katanaev, V.L. A direct and functional interaction between Go and Rab5 during G
protein-coupled receptor signaling. Sci. Signal. 2010. [CrossRef] [PubMed]
125. Lustberg, M.B.; Pant, S.; Ruppert, A.S.; Shen, T.; Wei, Y.; Chen, L.; Brenner, L.; Shiels, D.; Jensen, R.R.;
Berger, M.; et al. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic
breast cancer treated with prior taxanes. Cancer Chemother. Pharmacol. 2012, 70, 49–56. [CrossRef] [PubMed]
126. Gradishar, W.J.; Soff, G.; Liu, J.; Cisneros, A.; French, S.; Rademaker, A.; Benson Iii, A.B.; Bouck, N. A pilot
trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. Oncology
2000, 58, 324–333. [CrossRef] [PubMed]
127. Falcone, A.; Pfanner, E.; Cianci, C.; Danesi, R.; Brunetti, I.; Del Tacca, M.; Conte, P.F. Suramin in patients with
metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. Cancer
1995, 75, 440–443. [CrossRef]
128. Falcone, A.; Pfanner, E.; Brunetti, I.; Allegrini, G.; Lencioni, M.; Galli, C.; Masi, G.; Danesi, R.; Antonuzzo, A.;
Del Tacca, M.; et al. Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic
colorectal cancer patients resistant to 5-FU+LV-based chemotherapy. Tumori 1998, 84, 666–668. [PubMed]
129. Lam, E.T.; Au, J.L.; Otterson, G.A.; Guillaume Wientjes, M.; Chen, L.; Shen, T.; Wei, Y.; Li, X.; Bekaii-Saab, T.;
Murgo, A.J.; et al. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine
therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother. Pharmacol. 2010, 66,
1019–1029. [CrossRef] [PubMed]
Cancers 2016, 8, 66 23 of 27
130. Hutson, P.R.; Tutsch, K.D.; Rago, R.; Arzoomanian, R.; Alberti, D.; Pomplun, M.; Church, D.; Marnocha, R.;
Cheng, A.L.; Kehrli, N.; et al. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of
suramin. Clin. Cancer Res. 1998, 4, 1429–1436. [PubMed]
131. Bowden, C.J.; Figg, W.D.; Dawson, N.A.; Sartor, O.; Bitton, R.J.; Weinberger, M.S.; Headlee, D.;
Reed, E.; Myers, C.E.; Cooper, M.R. A phase I/II study of continuous infusion suramin in patients with
hormone-refractory prostate cancer: Toxicity and response. Cancer Chemother. Pharmacol. 1996, 39, 1–8.
[CrossRef] [PubMed]
132. Figg, W.D.; Cooper, M.R.; Thibault, A.; Headlee, D.; Humphrey, J.; Bergan, R.C.; Reed, E.; Sartor, O. Acute
renal toxicity associated with suramin in the treatment of prostate cancer. Cancer 1994, 74, 1612–1614.
[CrossRef]
133. Sridhara, R.; Eisenberger, M.A.; Sinibaldi, V.J.; Reyno, L.M.; Egorin, M.J. Evaluation of prostate-specific
antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
J. Clin. Oncol. 1995, 13, 2944–2953. [PubMed]
134. Kaur, M.; Reed, E.; Sartor, O.; Dahut, W.; Figg, W.D. Suramin’s development: What did we learn?
Invest. New Drugs 2002, 20, 209–219. [CrossRef] [PubMed]
135. Ord, J.J.; Streeter, E.; Jones, A.; Le Monnier, K.; Cranston, D.; Crew, J.; Joel, S.P.; Rogers, M.A.; Banks, R.E.;
Roberts, I.S.; et al. Phase I trial of intravesical suramin in recurrent superficial transitional cell bladder
carcinoma. Br. J. Cancer 2005, 92, 2140–2147. [CrossRef] [PubMed]
136. Mastrangelo, E.; Mazzitelli, S.; Fabbri, J.; Rohayem, J.; Ruokolainen, J.; Nykanen, A.; Milani, M.; Pezzullo, M.;
Nastruzzi, C.; Bolognesi, M. Delivery of suramin as an antiviral agent through liposomal systems.
Chemmedchem 2014, 9, 933–939. [CrossRef] [PubMed]
137. Sadashiva, M.P.; Basappa, S.; Nanjundaswamy, S.; Li, F.; Manu, K.A.; Sengottuvelan, M.; Prasanna, D.S.;
Anilkumar, N.C.; Sethi, G.; Sugahara, K.; et al. Anti-cancer activity of novel dibenzo[b,f]azepine tethered
isoxazoline derivatives. BMC Chem. Biol. 2012. [CrossRef]
138. Baghdiguian, S.; Nickel, P.; Fantini, J. Double screening of suramin derivatives on human colon cancer cells
and on neural cells provides new therapeutic agents with reduced toxicity. Cancer Lett. 1991, 60, 213–219.
[CrossRef]
139. McCain, D.F.; Wu, L.; Nickel, P.; Kassack, M.U.; Kreimeyer, A.; Gagliardi, A.; Collins, D.C.; Zhang, Z.Y.
Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases. J. Biol. Chem. 2004, 279,
14713–14725. [CrossRef] [PubMed]
140. Beck, J.W.; Saavedra, D.; Antell, G.J.; Tejeiro, B. The treatment of pinworm infections in humans (enterobiasis)
with pyrvinium chloride and pyrvinium pamoate. Am. J. Trop. Med. Hyg. 1959, 8, 349–352. [PubMed]
141. Wiegering, A.; Uthe, F.W.; Huttenrauch, M.; Muhling, B.; Linnebacher, M.; Krummenast, F.; Germer, C.T.;
Thalheimer, A.; Otto, C. The impact of pyrvinium pamoate on colon cancer cell viability. Int. J. Colorectal. Dis.
2014, 29, 1189–1198. [CrossRef] [PubMed]
142. Venerando, A.; Girardi, C.; Ruzzene, M.; Pinna, L.A. Pyrvinium pamoate does not activate protein kinase CK1,
but promotes Akt/PKB down-regulation and GSK3 activation. Biochem. J. 2013, 452, 131–137. [CrossRef]
[PubMed]
143. Thorne, C.A.; Hanson, A.J.; Schneider, J.; Tahinci, E.; Orton, D.; Cselenyi, C.S.; Jernigan, K.K.; Meyers, K.C.;
Hang, B.I.; Waterson, A.G.; et al. Small-molecule inhibition of Wnt signaling through activation of casein
kinase 1α. Nat. Chem. Biol. 2010, 6, 829–836. [CrossRef] [PubMed]
144. Tomitsuka, E.; Kita, K.; Esumi, H. An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate
reductase system—A unique mitochondrial energy metabolism in tumour microenvironments. J. Biochem.
2012, 152, 171–183. [CrossRef] [PubMed]
145. Harada, Y.; Ishii, I.; Hatake, K.; Kasahara, T. Pyrvinium pamoate inhibits proliferation of myeloma/
erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett. 2012, 319,
83–88. [CrossRef] [PubMed]
146. Yu, D.H.; Macdonald, J.; Liu, G.; Lee, A.S.; Ly, M.; Davis, T.; Ke, N.; Zhou, D.; Wong-Staal, F.; Li, Q.X.
Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by
combination therapy. PLoS ONE 2008, 3, e3951. [CrossRef] [PubMed]
147. Deng, L.; Lei, Y.; Liu, R.; Li, J.; Yuan, K.; Li, Y.; Chen, Y.; Liu, Y.; Lu, Y.; Edwards, C.K., 3rd; et al. Pyrvinium
targets autophagy addiction to promote cancer cell death. Cell Death Dis. 2013. [CrossRef] [PubMed]
Cancers 2016, 8, 66 24 of 27
148. Smith, T.C.; Kinkel, A.W.; Gryczko, C.M.; Goulet, J.R. Absorption of pyrvinium pamoate. Clin. Pharmacol. Ther.
1976, 19, 802–806. [CrossRef] [PubMed]
149. Jones, J.O.; Bolton, E.C.; Huang, Y.; Feau, C.; Guy, R.K.; Yamamoto, K.R.; Hann, B.; Diamond, M.I.
Non-competitive androgen receptor inhibition in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2009,
106, 7233–7238. [CrossRef] [PubMed]
150. Geary, T.G. Ivermectin 20 years on: Maturation of a wonder drug. Trends Parasitol. 2005, 21, 530–532.
[CrossRef] [PubMed]
151. Baraka, O.Z.; Mahmoud, B.M.; Marschke, C.K.; Geary, T.G.; Homeida, M.M.; Williams, J.F. Ivermectin
distribution in the plasma and tissues of patients infected with onchocerca volvulus. Eur. J. Clin. Pharmacol.
1996, 50, 407–410. [CrossRef] [PubMed]
152. Guzzo, C.A.; Furtek, C.I.; Porras, A.G.; Chen, C.; Tipping, R.; Clineschmidt, C.M.; Sciberras, D.G.; Hsieh, J.Y.;
Lasseter, K.C. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy
adult subjects. J. Clin. Pharmacol. 2002, 42, 1122–1133. [CrossRef] [PubMed]
153. Lynagh, T.; Lynch, J.W. Molecular mechanisms of cys-loop ion channel receptor modulation by ivermectin.
Front. Mol. Neurosci. 2012. [CrossRef] [PubMed]
154. Melotti, A.; Mas, C.; Kuciak, M.; Lorente-Trigos, A.; Borges, I.; Ruiz i Altaba, A. The river blindness
drug ivermectin and related macrocyclic lactones inhibit Wnt-TCF pathway responses in human cancer.
EMBOMol. Med. 2014, 6, 1263–1278. [CrossRef] [PubMed]
155. Sharmeen, S.; Skrtic, M.; Sukhai, M.A.; Hurren, R.; Gronda, M.; Wang, X.; Fonseca, S.B.; Sun, H.; Wood, T.E.;
Ward, R.; et al. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization
and cell death in leukemia cells. Blood 2010, 116, 3593–3603. [CrossRef] [PubMed]
156. Dadarkar, S.S.; Deore, M.D.; Gatne, M.M. Comparative evaluation of acute toxicity of ivermectin by two
methods after single subcutaneous administration in rats. Regul. Toxicol. Pharmacol. 2007, 47, 257–260.
[CrossRef] [PubMed]
157. Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R.A.; Lander, E.S. Identification of
selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138, 645–659. [CrossRef]
[PubMed]
158. He, L.; Wang, F.; Dai, W.-Q.; Wu, D.; Lin, C.-L.; Wu, S.-M.; Cheng, P.; Zhang, Y.; Shen, M.; Wang, C.-F.; et al.
Mechanism of action of salinomycin on growth and migration in pancreatic cancer cell lines. Pancreatology
2013, 13, 72–78. [CrossRef] [PubMed]
159. Kusunoki, S.; Kato, K.; Tabu, K.; Inagaki, T.; Okabe, H.; Kaneda, H.; Suga, S.; Terao, Y.; Taga, T.; Takeda, S.
The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial
cancer stem-like cells. Gynecol. Oncol. 2013, 129, 598–605. [CrossRef] [PubMed]
160. Lu, D.; Choi, M.Y.; Yu, J.; Castro, J.E.; Kipps, T.J.; Carson, D.A. Salinomycin inhibits Wnt signaling and
selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc. Natl. Acad. Sci. USA 2011, 108,
13253–13257. [CrossRef] [PubMed]
161. Lu, W.; Li, Y. Salinomycin suppresses LRP6 expression and inhibits both Wnt/beta-catenin and mTORC1
signaling in breast and prostate cancer cells. J. Cell. Biochem. 2014, 115, 1799–1807. [CrossRef] [PubMed]
162. Tang, Q.L.; Zhao, Z.Q.; Li, J.C.; Liang, Y.; Yin, J.Q.; Zou, C.Y.; Xie, X.B.; Zeng, Y.X.; Shen, J.N.; Kang, T.;
et al. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011, 311, 113–121.
[CrossRef] [PubMed]
163. Wang, F.; He, L.; Dai, W.Q.; Xu, Y.P.; Wu, D.; Lin, C.L.; Wu, S.M.; Cheng, P.; Zhang, Y.; Shen, M.; et al.
Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro
andin vivo. PLoS ONE 2012, 7, e50638.
164. Wu, D.; Zhang, Y.; Huang, J.; Fan, Z.; Shi, F.; Wang, S. Salinomycin inhibits proliferation and induces apoptosis
of human nasopharyngeal carcinoma cell in vitro and suppresses tumor growthin vivo. Biochem. Biophys.
Res. Commun. 2014, 443, 712–717. [CrossRef] [PubMed]
165. Mao, J.; Fan, S.; Ma, W.; Fan, P.; Wang, B.; Zhang, J.; Wang, H.; Tang, B.; Zhang, Q.; Yu, X.; et al.
Roles of Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment.
Cell Death Dis. 2014. [CrossRef] [PubMed]
166. Zhou, Y.; Liang, C.; Xue, F.; Chen, W.; Zhi, X.; Feng, X.; Bai, X.; Liang, T. Salinomycin decreases doxorubicin
resistance in hepatocellular carcinoma cells by inhibiting the beta-catenin/TCF complex association via
FOXO3a activation. Oncotarget 2015, 6, 10350–10365. [CrossRef] [PubMed]
Cancers 2016, 8, 66 25 of 27
167. Naujokata, C.; Lauferc, S. Targeting cancer stem cells with defined compounds and drugs. J. Cancer
Res. Updates 2013, 2, 36–67. [CrossRef]
168. Lagas, J.S.; Sparidans, R.W.; van Waterschoot, R.A.; Wagenaar, E.; Beijnen, J.H.; Schinkel, A.H. P-glycoprotein
limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.
Antimicrob. Agents Chemother. 2008, 52, 1034–1039. [CrossRef] [PubMed]
169. Naujokat, C.; Steinhart, R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol.
2012. [CrossRef] [PubMed]
170. Koval, A.V.; Vlasov, P.; Shichkova, P.; Khunderyakova, S.; Markov, Y.; Panchenko, J.; Volodina, A.;
Kondrashov, F.A.; Katanaev, V.L. Anti-leprosy drug clofazimine inhibits growth of triple-negative breast
cancer cells via inhibition of canonical Wnt signaling. Biochem. Pharmacol. 2014, 87, 571–578. [CrossRef]
[PubMed]
171. Van Rensburg, C.E.; van Staden, A.M.; Anderson, R. The riminophenazine agents clofazimine and
B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and
nonoxidative mechanisms. Cancer Res. 1993, 53, 318–323. [PubMed]
172. Sri-Pathmanathan, R.M.; Plumb, J.A.; Fearon, K.C. Clofazimine alters the energy metabolism and inhibits the
growth rate of a human lung-cancer cell line in vitro and in vivo. Int. J. Cancer 1994, 56, 900–905. [CrossRef]
[PubMed]
173. Nix, D.E.; Adam, R.D.; Auclair, B.; Krueger, T.S.; Godo, P.G.; Peloquin, C.A. Pharmacokinetics and relative
bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis 2004, 84, 365–373.
[CrossRef] [PubMed]
174. Vanrensburg, C.; Durandt, C.; Garlinski, P.; Osullivan, J. Evaluation of the antineoplastic activities of the
riminophenazine agents clofazimine and B669 in tumor-bearing rats and mice. Int. J. Oncol. 1993, 3,
1011–1013. [CrossRef] [PubMed]
175. Ruff, P.; Chasen, M.R.; Long, J.E.; van Rensburg, C.E. A phase II study of oral clofazimine in unresectable
and metastatic hepatocellular carcinoma. Ann. Oncol. 1998, 9, 217–219. [CrossRef] [PubMed]
176. Falkson, C.I.; Falkson, G. A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable
primary hepatocellular carcinoma. Oncology 1999, 57, 232–235. [CrossRef] [PubMed]
177. O’Connor, R.; O’Sullivan, J.F.; O’Kennedy, R. The pharmacology, metabolism, and chemistry of clofazimine.
Drug Metab. Rev. 1995, 27, 591–614. [CrossRef] [PubMed]
178. Li, H.; Jiao, S.; Li, X.; Banu, H.; Hamal, S.; Wang, X. Therapeutic effects of antibiotic drug tigecycline against
cervical squamous cell carcinoma by inhibiting Wnt/β-catenin signaling. Biochem. Biophys. Res. Commun.
2015, 467, 14–20. [CrossRef] [PubMed]
179. Bolzan, A.D.; Bianchi, M.S. Genotoxicity of streptonigrin: A review. Mutat. Res. 2001, 488, 25–37. [CrossRef]
180. Harris, M.N.; Medrek, T.J.; Golomb, F.M.; Gumport, S.L.; Postel, A.H.; Wright, J.C. Chemotherapy with
streptonigrin in advanced cancer. Cancer 1965, 18, 49–57. [CrossRef]
181. Park, S.; Chun, S. Streptonigrin inhibits β-catenin/tcf signaling and shows cytotoxicity in
beta-catenin-activated cells. Biochim. Biophys. Acta 2011, 1810, 1340–1345. [CrossRef] [PubMed]
182. Park, S.; Gwak, J.; Cho, M.; Song, T.; Won, J.; Kim, D.E.; Shin, J.G.; Oh, S. Hexachlorophene inhibits
Wnt/β-catenin pathway by promoting Siah-mediated β-catenin degradation. Mol. Pharmacol. 2006, 70,
960–966. [CrossRef] [PubMed]
183. Min, H.J.; Cho, I.R.; Srisuttee, R.; Park, E.H.; Cho, D.H.; Ahn, J.H.; Lee, I.S.; Johnston, R.N.; Oh, S.; Chung, Y.H.
Hexachlorophene suppresses β-catenin expression by up-regulation of Siah-1 in EBV-infected B lymphoma
cells. Cancer Lett. 2009, 276, 136–142. [CrossRef] [PubMed]
184. Bowker, S.L.; Majumdar, S.R.; Veugelers, P.; Johnson, J.A. Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29, 254–258. [CrossRef] [PubMed]
185. Hou, G.; Zhang, S.; Zhang, X.; Wang, P.; Hao, X.; Zhang, J. Clinical pathological characteristics and prognostic
analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res. Treat. 2013, 137, 807–816. [CrossRef]
[PubMed]
186. Kwan, H.T.; Chan, D.W.; Cai, P.C.H.; Mak, C.S.L.; Yung, M.M.H.; Leung, T.H.Y.; Wong, O.G.W.;
Cheung, A.N.Y.; Ngan, H.Y.S. Ampk activators suppress cervical cancer cell growth through inhibition of
Dvl3 mediated Wnt/β-catenin signaling activity. PLoS ONE 2013, 8, e53597. [CrossRef] [PubMed]
Cancers 2016, 8, 66 26 of 27
187. Zhou, G.C.; Myers, R.; Li, Y.; Chen, Y.L.; Shen, X.L.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.;
et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108,
1167–1174. [CrossRef] [PubMed]
188. Chae, Y.K.; Arya, A.; Malecek, M.K.; Shin, D.S.; Carneiro, B.; Chandra, S.; Kaplan, J.; Kalyan, A.; Altman, J.K.;
Platanias, L.; et al. Repurposing metformin for cancer treatment: Current clinical studies. Oncotarget 2016.
[CrossRef] [PubMed]
189. Eikawa, S.; Nishida, M.; Mizukami, S.; Yamazaki, C.; Nakayama, E.; Udono, H. Immune-mediated antitumor
effect by type 2 diabetes drug, metformin. Proc. Natl. Acad. Sci. USA 2015, 112, 1809–1814. [CrossRef]
[PubMed]
190. Ashinuma, H.; Takiguchi, Y.; Kitazono, S.; Kitazono-Saitoh, M.; Kitamura, A.; Chiba, T.; Tada, Y.; Kurosu, K.;
Sakaida, E.; Sekine, I.; et al. Antiproliferative action of metformin in human lung cancer cell lines. Oncol. Rep.
2012, 28, 8–14. [PubMed]
191. Gong, J.; Robbins, L.A.; Lugea, A.; Waldron, R.T.; Jeon, C.Y.; Pandol, S.J. Diabetes, pancreatic cancer, and
metformin therapy. Front. Physiol. 2014. [CrossRef] [PubMed]
192. Kato, K.; Gong, J.; Iwama, H.; Kitanaka, A.; Tani, J.; Miyoshi, H.; Nomura, K.; Mimura, S.; Kobayashi, M.;
Aritomo, Y.; et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and
in vivo. Mol. Cancer Ther. 2012, 11, 549–560. [CrossRef] [PubMed]
193. Shank, J.J.; Yang, K.; Ghannam, J.; Cabrera, L.; Johnston, C.J.; Reynolds, R.K.; Buckanovich, R.J. Metformin
targets ovarian cancer stem cells in vitro and in vivo. Gynecol. Oncol. 2012, 127, 390–397. [CrossRef]
[PubMed]
194. Zhou, X.; Chen, J.; Yi, G.; Deng, M.; Liu, H.; Liang, M.; Shi, B.; Fu, X.; Chen, Y.; Chen, L.; et al. Metformin
suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in
hepatocellular carcinoma. Oncotarget 2016, 7, 873–884. [CrossRef] [PubMed]
195. Pardanani, A.; Tefferi, A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.
Blood 2004, 104, 1931–1939. [CrossRef] [PubMed]
196. Rao, A.S.; Kremenevskaja, N.; von Wasielewski, R.; Jakubcakova, V.; Kant, S.; Resch, J.; Brabant, G.
Wnt/β-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid
cancer. J. Clin. Endocrinol. Metab. 2006, 91, 159–168. [CrossRef] [PubMed]
197. Zhou, L.; An, N.; Haydon, R.C.; Zhou, Q.; Cheng, H.; Peng, Y.; Jiang, W.; Luu, H.H.; Vanichakarn, P.;
Szatkowski, J.P.; et al. Tyrosine kinase inhibitor STI-571/gleevec down-regulates the β-catenin signaling
activity. Cancer Lett. 2003, 193, 161–170. [CrossRef]
198. Lu, D.; Liu, J.X.; Endo, T.; Zhou, H.; Yao, S.; Willert, K.; Schmidt-Wolf, I.G.; Kipps, T.J.; Carson, D.A. Ethacrynic
acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/β-catenin
pathway. PLoS ONE 2009, 4, e8294. [CrossRef] [PubMed]
199. Schmidt, M.; Kim, Y.; Gast, S.M.; Endo, T.; Lu, D.; Carson, D.; Schmidt-Wolf, I.G. Increased in vivo efficacy of
lenalidomide and thalidomide by addition of ethacrynic acid. In Vivo 2011, 25, 325–333. [PubMed]
200. Kim, Y.; Gast, S.M.; Endo, T.; Lu, D.; Carson, D.; Schmidt-Wolf, I.G. In vivo efficacy of the diuretic agent
ethacrynic acid against multiple myeloma. Leuk. Res. 2012, 36, 598–600. [CrossRef] [PubMed]
201. Lacreta, F.P.; Brennan, J.M.; Nash, S.L.; Comis, R.L.; Tew, K.D.; O’Dwyer, P.J. Pharmakokinetics and
bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J. Pharmacol.
Exp. Ther. 1994, 270, 1186–1191. [PubMed]
202. Webster, M.R.; Weeraratna, A.T. A Wnt-er migration: The confusing role of β-catenin in melanoma metastasis.
Sci. Signal. 2013. [CrossRef] [PubMed]
203. Chien, A.J.; Moore, E.C.; Lonsdorf, A.S.; Kulikauskas, R.M.; Rothberg, B.G.; Berger, A.J.; Major, M.B.;
Hwang, S.T.; Rimm, D.L.; Moon, R.T. Activated Wnt/β-catenin signaling in melanoma is associated with
decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl. Acad. Sci. USA 2009,
106, 1193–1198. [CrossRef] [PubMed]
204. Biechele, T.L.; Camp, N.D.; Fass, D.M.; Kulikauskas, R.M.; Robin, N.C.; White, B.D.; Taraska, C.M.;
Moore, E.C.; Muster, J.; Karmacharya, R.; et al. Chemical-genetic screen identifies riluzole as an enhancer of
Wnt/β-catenin signaling in melanoma. Chem. Biol. 2010, 17, 1177–1182. [CrossRef] [PubMed]
205. Yip, D.; Le, M.N.; Chan, J.L.; Lee, J.H.; Mehnert, J.A.; Yudd, A.; Kempf, J.; Shih, W.J.; Chen, S.; Goydos, J.S.
A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin.Cancer Res. 2009, 15,
3896–3902. [CrossRef] [PubMed]
Cancers 2016, 8, 66 27 of 27
206. Clevers, H.; Loh, K.M.; Nusse, R. Stem cell signaling. An integral program for tissue renewal and
regeneration: Wnt signaling and stem cell control. Science 2014. [CrossRef] [PubMed]
207. Novac, N. Challenges and opportunities of drug repositioning. Trends Pharmacol. Sci. 2013, 34, 267–272.
[CrossRef] [PubMed]
208. Mook, R.A., Jr.; Wang, J.; Ren, X.R.; Chen, M.; Spasojevic, I.; Barak, L.S.; Lyerly, H.K.; Chen, W.
Structure-activity studies of Wnt/β-catenin inhibition in the niclosamide chemotype: Identification of
derivatives with improved drug exposure. Bioorg. Med. Chem. 2015, 23, 5829–5838. [CrossRef] [PubMed]
209. Jin, G.; Lu, D.; Yao, S.; Wu, C.C.; Liu, J.X.; Carson, D.A.; Cottam, H.B. Amide derivatives of ethacrynic
acid: Synthesis and evaluation as antagonists of Wnt/β-catenin signaling and cll cell survival. Bioorg. Med.
Chem. Lett. 2009, 19, 606–609. [CrossRef] [PubMed]
210. Huczynski, A.; Janczak, J.; Antoszczak, M.; Wietrzyk, J.; Maj, E.; Brzezinski, B. Antiproliferative activity of
salinomycin and its derivatives. Bioorg. Med. Chem. Lett. 2012, 22, 7146–7150. [CrossRef] [PubMed]
211. Huang, X.; Borgstrom, B.; Kempengren, S.; Persson, L.; Hegardt, C.; Strand, D.; Oredsson, S. Breast cancer
stem cell selectivity of synthetic nanomolar-active salinomycin analogs. BMC Cancer 2016. [CrossRef]
[PubMed]
212. Goluboff, E.T.; Shabsigh, A.; Saidi, J.A.; Weinstein, I.B.; Mitra, N.; Heitjan, D.; Piazza, G.A.; Pamukcu, R.;
Buttyan, R.; Olsson, C.A. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude
mouse xenograft model by increasing apoptosis. Urology 1999, 53, 440–445. [CrossRef]
213. Piazza, G.A.; Keeton, A.B.; Tinsley, H.N.; Gary, B.D.; Whitt, J.D.; Mathew, B.; Thaiparambil, J.; Coward, L.;
Gorman, G.; Li, Y.; et al. A novel sulindac derivative that does not inhibit cyclooxygenases but potently
inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev. Res. 2009, 2,
572–580. [CrossRef] [PubMed]
214. Rigas, B. Novel agents for cancer prevention based on nitric oxide. Biochem. Soc. Trans. 2007, 35, 1364–1368.
[CrossRef] [PubMed]
215. Rigas, B.; Tsioulias, G.J. The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention:
A cause for optimism. J. Pharmacol. Exp. Ther. 2015, 353, 2–8. [CrossRef] [PubMed]
216. Gerhart, J. 1998 warkany lecture: Signaling pathways in development. Teratology 1999, 60, 226–239. [CrossRef]
217. Sekulic, A.; von Hoff, D. Hedgehog pathway inhibition. Cell 2016. [CrossRef] [PubMed]
218. Barker, N.; Clevers, H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5,
997–1014. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
